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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 06, Revision 2 
(FGE.06Rev2): 
Straight- and branched-chain aliphatic unsaturated primary alcohols, 
aldehydes, carboxylic acids, and esters from chemical groups 1 and 41 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate the 48 flavouring substances in 
this Flavouring Group Evaluation 06, Revision 2 (FGE.06Rev2), using the Procedure as referred to in 
the Commission Regulation (EC) No 1565/2000. These 48 flavouring substances belong to chemical 
groups 1 and 4, Annex I of the Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation deals with 48 straight- and branched-chain unsaturated 
primary alcohols, aldehydes, carboxylic acids and esters.  
Eight of the 48  flavouring substances possess a chiral centre [FL-no: 02.170, 02.175, 05.143, 09.341, 
09.612, 09.871, 09.872 and 09.938]. 
Thirty-one of the 48 substances can exist as geometrical isomers [FL-no: 02.152, 02.195, 02.222, 
02.234, 05.061, 05.082, 05.203, 05.217, 05.218, 05.220, 08.074, 08.102, 09.377, 09.567, 09.569, 
09.572, 09.575, 09.638, 09.640, 09.643, 09.672, 09.673, 09.674, 09.831, 09.838, 09.855, 09.884, 
09.885, 09.928, 09.937 and 09.939]. For 13 of these substances [FL-no: 02.152, 02.222, 05.061, 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2010-01131, adopted on 30 September 2010. 
2  Panel members Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude 
Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, Detlef 
Wölfle. Correspondence: cef-unit@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, 
Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, 
Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the 
preparatory work on this scientific Opinion. 
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05.203, 05.218, 08.074, 08.102, 09.377, 09.640, 09.674, 09.831, 09.884, 09.885] no indication has 
been given that one of the possible isomers has preponderance in the commercial flavouring material.  
Forty-six candidate substances are classified into structural class I. The remaining two substances [FL-
no: 05.143 and 09.884] are classified into structural class II. 
Thirty-eight of the flavouring substances in the present group have been reported to occur naturally in 
a wide range of food items. 
According to the default MSDI approach, the 48 flavouring substances in this group have intakes in 
Europe from 0.001 to 120 microgram/capita/day, which are below the thresholds of concern value for 
both structural class I (1800 microgram/person/day) and structural class II (540 
microgram/person/day) substances.  
On the basis of the reported annual production volumes in Europe (MSDI approach), the combined 
intake of the 46 candidate substances belonging to structural class I and of the two candidate 
substances belonging to structural class II would result in a total intake of approximately 255 and 0.7 
microgram/capita/day, respectively. These values are below the thresholds of concern for structural 
class I and class II substances of 1800 and 540 microgram/person/day, respectively. The total 
combined estimated intake of 65 of the 70 supporting substances for which European annual 
production data are available and of the 46 candidate substances from structural class I is 
approximately 6700 microgram/capita/day, which exceeds the threshold of concern for structural class 
I (1800 microgram/person/day). However, the substances are expected to be efficiently metabolised 
and are not expected to saturate the metabolic pathways. 
For the substances in this group the limited data available do not give rise to safety concern with 
respect to genotoxicity and carcinogenicity.   
Except for hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] the candidate substances are expected to be 
metabolised to innocuous substances at the estimated levels of use as flavouring substances. One of 
the hydrolysis products of [FL-no: 09.884], 2-ethylbutyric acid, showed teratogenic potential in one 
mouse subcutaneous single-dose study, and is structurally related to valproic acid, which is a known 
teratogen. However, an additional study in which 2-ethylbutyric acid was given by gavage to pregnant 
rats showed a NOAEL of 200 mg/kg bw/day of 2-ethylbutyric acid. This dose is more than 4 x 107 
times higher than the MSDI for 2-ethylbutyric acid arising from the intake of the candidate substance, 
[FL-no: 09.884]. Accordingly, the candidate substance [FL-no: 09.884] does not pose a safety concern 
with respect to teratogenicity when used at the level of intake as flavouring substance estimated on the 
basis of the MSDI approach. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that on the basis of the default MSDI approach these 48  candidate substances would 
not give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances. 
When the estimated intakes were based on the mTAMDI approach they ranged from 36 to 40000 
microgram/person/day for the 45 flavouring substances from structural class I for which data have 
been provided. Thus, the intakes were all above the threshold of concern for structural class I of 1800 
microgram/person/day, except for nine flavouring substances [FL-no: 05.061, 05.174, 05.082, 05.203, 
05.217, 05.218, 05.220, 09.937 and 09.939]. The estimated intakes of the two flavouring substances 
assigned to structural class II, based on the mTAMDI are 1600 and 3900 microgram/person/day, 
which is above the threshold of concern for structural class II of 540 microgram/person/day. The nine 
substances [FL-no: 05.061, 05.174, 05.082, 05.203, 05.217, 05.218, 05.220, 09.937 and 09.939], 
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which have mTAMDI intake estimates below the threshold of concern for structural class I, are also 
expected to be metabolised to innocuous products.  
Thus, for 38 of the 48 flavouring substances considered in this Opinion, the intakes, estimated on the 
basis of the mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring 
substance has been assigned. For one substance [FL-no: 09.647] no use levels were provided. 
Therefore, for these 39 substances more reliable exposure data are required. On the basis of such 
additional data, these flavouring substances should be reconsidered along the steps of the Procedure. 
Subsequently, additional data might become necessary.  
In order to determine whether the conclusion for the 48 candidate substances can be applied to the 
material of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
46 of the 48 flavouring candidate substances. An ID test is missing for [FL-no: 09.938] and a boiling 
point is lacking for [FL-no: 09.674]. Otherwise the specifications are adequate for all 48 candidate 
substances, except that information on composition of stereoisomeric mixture has not been specified 
sufficiently for 13 of the substances [FL-no: 02.152, 02.222, 05.061, 05.203, 05.218, 08.074, 08.102, 
09.377, 09.640, 09.674, 09.831, 09.884 and 09.885].  
Thus, the final evaluation of the materials of commerce cannot be performed for 14 substances [FL-
no: 02.152, 02.222, 05.061, 05.203, 05.218, 08.074, 08.102, 09.377, 09.640, 09.674, 09.831, 09.884, 
09.885 and 09.938], pending further information. The remaining 34 substances [FL-no: 02.125, 
02.138, 02.170, 02.175, 02.176, 02.195, 02.201, 02.234, 05.082, 05.143, 05.174, 05.217, 05.220, 
08.100, 09.341, 09.368, 09.567, 09.569, 09.572, 09.575, 09.612, 09.638, 09.643, 09.672, 09.673, 
09.838, 09.855, 09.871, 09.872, 09.897, 09.898, 09.928, 09.937 and 09.939] would present no safety 
concern at the levels of intake estimated on the basis of the MSDI approach. 
 
KEYWORDS 
Straight-chain, branched-chain, unsaturated, primary alcohols, aldehydes, carboxylic acids, esters, flavourings, 
safety. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION  
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.06 7 October 2004 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1178620762005.htm 
35 
FGE.06Rev1 7 February 2007 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1178710471245.htm 
47 
FGE.06Rev2 29 September 2010  48 
 
The present revision of FGE.06, FGE.06Rev2, includes the assessment of one additional candidate 
substance [FL-no: 09.674]. 
No toxicity or metabolism data were provided for this substance. A search in open literature did not 
provide any further data on toxicity or metabolism for this substance. 
 
Furthermore, information from Industry on missing specifications received after publication of the last 
revision is included in the present revision. (EFFA, 2010a). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 
evaluation programme. 
Flavouring Group Evaluation 06, Revision 2 
 
 
6 EFSA Journal 2011;9(3):1844 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 06, Revision 2 
1.1. Description 
The present Flavouring Group Evaluation 6 Revision 2, FGE.06Rev2, using the Procedure as referred 
to in the Commission Regulation (EC) No 1565/2000 (the Procedure – shown in schematic form in 
Annex I of this FGE), deals with 48  straight- and branched-chain aliphatic unsaturated primary 
alcohols, aldehydes, carboxylic acids and esters. These 48  flavouring substances (candidate 
substances) belong to chemical groups 1 and 4 of Annex I of Regulation (EC) No 1565/2000 (EC, 
2000a). 
The 48 flavouring substances under consideration, with their chemical Register name, FLAVIS (FL-), 
Chemical Abstract Service (CAS-), Council of Europe (CoE-), and Flavor and Extract Manufacturers’ 
Association (FEMA-) numbers, structure and specifications, are listed in Table 1. This group of 
candidate flavouring substances includes 27 straight or branched-chain esters [FL-no: 09.341, 09.368, 
09.377, 09.567, 09.569, 09.572, 09.575, 09.612, 09.638, 09.640, 09.643, 09.672, 09.673, 09.674, 
09.831, 09.838, 09.855, 09.871, 09.872, 09.884, 09.885, 09.897, 09.898, 09.928, 09.937, 09.938 and 
09.939], ten straight or branched-chain alcohols [FL-no: 02.125, 02.138, 02.152, 02.170, 02.175, 
02.176, 02.195, 02.201, 02.222 and 02.234], eight straight or branched-chain aldehydes [FL-no: 
05.061, 05.082, 05.143, 05.174, 05.203, 05.217, 05.218 and 05.220], and three straight or branched-
chain carboxylic acids [FL-no: 08.074, 08.100 and 08.102].  
The outcome of the safety evaluation is summarised in Table 2a. 
The hydrolysis products of the candidate esters are listed in Table 2b. 
The 48  candidate substances are structurally related to flavouring substances (supporting substances) 
evaluated at the 49th, 51st or 61st meetings of the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) (JECFA, 1999b; JECFA, 2000a; JECFA, 2004a). That is, they are structurally 
related to 26 esters derived from branched-chain terpenoid alcohols and aliphatic acyclic linear and 
branched-chain carboxylic acids (JECFA, 1998a) or to 44 linear and branched-chain aliphatic, 
unsaturated, unconjugated alcohols, aldehydes, carboxylic acids and related esters (JECFA, 1999a; 
JECFA, 2004a), previously evaluated by the JECFA. The names and structures of the 70 supporting 
substances are listed in Table 3, together with their evaluation status (CoE, 1992; JECFA, 1999b; 
JECFA, 2000a; JECFA, 2004a; SCF, 1995).  
Additional substances evaluated by the JECFA and structurally related to the 70 supporting substances 
are also taken into consideration in FGE.06Rev2 regarding toxicity and metabolism studies. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
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Eight of the 48 flavouring substances possess a chiral centre [FL-no: 02.170, 02.175, 05.143, 09.341, 
09.612, 09.871, 09.872 and 09.938].  
Due to the presence and the position of double bonds, 31 of the 48 substances can exist as geometrical 
isomers [FL-no: 02.152, 02.195, 02.222, 02.234, 05.061, 05.082, 05.203, 05.217, 05.218, 05.220, 
08.074, 08.102, 09.377, 09.567, 09.569, 09.572, 09.575, 09.638, 09.640, 09.643, 09.672, 09.673, 
09.674, 09.831, 09.838, 09.855, 09.884, 09.885, 09.928, 09.937 and 09.939]. The geometrical 
isomeric form is clear for only 18 substances: [FL-no: 02.195, 02.234, 05.082, 05.217, 05.220, 09.567, 
09.569, 09.572, 09.575, 09.638, 09.643, 09.672, 09.673, 09.838, 09.855, 09.928, 09.937 and 09.939]. 
In the remaining 13 cases [FL-no: 02.152, 02.222, 05.061, 05.203, 05.218, 08.074, 08.102, 09.377, 
09.640, 09.674, 09.831, 09.884 and 09.885], no indication has been given that one of the possible 
isomers has preponderance in the commercial flavouring material (see Table 1). For 12 of these 13 
flavouring substances [FL-no: 02.152, 02.222, 05.061, 05.203, 05.218, 08.074, 08.102, 09.377, 
09.640, 09.831, 09.884 and 09.885] Industry has informed that they exist as a “mixture of isomers” 
2010a) (see Table 1). However, the Panel does not consider this information sufficient and requests 
data on the actual ratios. For [FL-no: 09.674] the stereoisomeric composition has to be specified. 
1.3. Natural Occurrence in Food 
Thirty-eight of the 48 candidate substances have been reported to occur naturally in fruits, essential 
oils, tea, herbs, mushrooms, beer, wine, beverage, meat, pork fat, cheese and/or butter (TNO, 2000).  
Quantitative data on the natural occurrence in food have been reported for 21 of the 38 substances.  
These reports include among other: 
• 2-Methylbut-3-en-1-ol [FL-no: 02.175]: up to 1.1 mg/kg in guava fruit 
• Hex-4-enyl acetate [FL-no: 09.572]: 1.56 mg/kg (Z-isomer) and < 0.05 mg/kg (E-isomer) in 
banana 
• 3-Methylbut-3-en-1-ol [FL-no: 02.176]: 0.001 mg/kg in roasted chicken and up to 0.12 mg/kg 
in wine 
• 4-Methylpent-3-enoic acid [FL-no: 08.100]: 0.32 mg/kg in beer 
• 9-Octadecenal [FL-no: 05.203]: 2 mg/kg in roasted chicken 
• trans-3-Hexenyl acetate [FL-no: 09.928]: up to 0.05 mg/kg in banana, up to 0.01 mg/kg in 
guava fruit, up to 0.005 mg/kg in mango and up to 0.01 mg/kg in passiflora 
• Methyl (3Z)-hexenoate [FL-no: 09.937]: up to 0.25 mg/kg in guava fruit 
• Ethyl (3Z)-hexenoate [FL-no: 09.939]: up to 0.15 mg/kg in passiflora juice. 
 
Twenty-six of the 38 candidate substances which have been reported to occur naturally in food can 
exist as geometrical isomers. For six of these 26 flavourings [FL-no: 08.074, 09.567, 09.575, 09.672, 
09.673 and 09.885] natural occurrence in food has only been reported for the Z-isomer (TNO, 2000).  
According to the Flavour Industry three of the candidate substances [FL-no: 05.061, 05.217, 05.218 
and 09.674] in the present group are of artificial origin and have not been reported to occur naturally 
in foods (EFFA, 2002d; EFFA, 2004u; Flavour Industry, 2008f). 
2. Specifications 
Purity criteria for the 48 candidate substances have been provided by the Flavour Industry (EFFA, 
2001c; EFFA, 2002b; EFFA, 2004u; Flavour Industry, 2004a; EFFA, 2006c; Flavour Industry, 2008f). 
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Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), the purity criteria for two of the candidate substances [FL-no: 09.674 and 09.938] is 
insufficient. An ID test is missing for [FL-no: 09.938] and a boiling point is lacking for [FL-no: 
09.674]. Otherwise the specifications are adequate for all 48 candidate substances, except that 
information on composition of stereoisomeric mixture has not been specified sufficiently for 13 
substances (see Section 1.2 and Table 1).  
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
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Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the present Flavouring Group Evaluation (FGE.06Rev2) the total annual volume of production of 
the 48 candidate substances from use as flavouring substances in Europe has been reported to be 
approximately 2200 kg (EFFA, 2001c; EFFA, 2002c; EFFA, 2004v; EFFA, 2006d; EFFA, 2008b; 
Flavour Industry, 2004a). For 65 of the 70 supporting substances the total annual volume of 
production is approximately 52000 kg (JECFA, 1999b; JECFA, 2000a; EFFA, 2002c). The annual 
volumes of production in Europe for five of the substances [FL-no: 02.110, 08.059, 09.141, 09.646 
and 09.927] were not reported. 
On the basis of the annual volume of production reported for the 48 candidate substances, MSDI 
values for each of these flavourings have been estimated (Table 2a).  
About 94 % of the total annual volume of production for the candidate substances is accounted for by 
two flavourings methyl (3Z)-hexenoate [FL-no: 09.937] and ethyl (3Z)-hexenoate [FL-no: 09.939]. 
The estimated MSDI values of methyl (3Z)-hexenoate and of ethyl (3Z)-hexenoate from use as 
flavouring substances are 120 microgram/capita/day. For all the remaining candidate substances the 
estimated daily per capita intakes are below 2 microgram (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the 48 candidate substances, information on food categories and normal 
and maximum use levels5,6,7 were submitted by the Flavour Industry for 47 of the 48  candidate 
substances (EFFA, 2001c; EFFA, 2002a; EFFA, 2004v; EFFA, 2006d; EFFA, 2007a; Flavour 
Industry, 2004a). For these 47 substances the use  in flavoured food products divided into the food 
categories, outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000a), is  
shown in Table 3.1. For the present calculation of mTAMDI, the reported normal use levels were 
used. In the case where different normal use levels were reported for different food categories the 
highest reported normal use level was used. 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile 
of reported usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from 
figures derived from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 
14.2 “Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 
2007a). 
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Table 3.1 Use of Candidate Substances 
Food 
category 
Description Flavourings used * 
01.0 Dairy products, excluding products of category 2 47 except [FL-no: 02.125] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 47 except [FL-no: 02.125, 
05.220] 
03.0 Edible ices, including sherbet and sorbet 47 
04.1 Processed fruits 47 except [FL-no: 02.125] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses 
and legumes), and nuts & seeds 
Only [FL-no: 09.928, 09.937, 
09.938, 09.939] 
05.0 Confectionery 47 
06.0 Cereals and cereal products, incl. flours & starches from roots & 
tubers, pulses & legumes, excluding bakery 
47 except [FL-no: 02.125, 
02.234] 
07.0 Bakery wares  47 except [FL-no: 02.125] 
08.0 Meat and meat products, including poultry and game  47 except [FL-no: 02.125, 
05.220] 
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
47 except [FL-no: 02.125, 
05.220] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc.  47 except [FL-no: 02.125, 
05.143, 05.220] 
13.0 Foodstuffs intended for particular nutritional uses  47 except [FL-no: 02.125, 
05.143, 05.220, 09.937, 
09.938, 09.939] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 47 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 47 
15.0 Ready-to-eat savouries 47 except [FL-no: 02.125] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that 
could not be placed in categories 1 – 15 
47 except [FL-no: 02.125, 
05.220] 
* No use levels have been submitted for [FL-no: 09.674] 
According to the Flavour Industry the normal use levels for the candidate substances are in the range 
of 0.02 – 100 mg/kg food, and the maximum use levels are in the range of 0.1 to 500 mg/kg (EFFA, 
2001c; EFFA, 2002a; EFFA, 2004v; EFFA, 2006d; EFFA, 2007a; Flavour Industry, 2004a). 
Information on use levels have not been provided for [FL-no: 09.674]. 
The mTAMDI values for the 45 candidate substances from structural class I for which data have been 
provided (see Section 6) range from 36 to 40000 microgram/person/day. For the remaining two 
candidate substances from structural class II the mTAMDI is 1600 and 3900 microgram/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
any of the candidate substances. 
The aliphatic alcohols, aldehydes and carboxylic acids in the present flavouring group are all expected 
to be absorbed from the gastrointestinal tract. Aliphatic esters are expected to be hydrolysed in the gut 
to yield the corresponding alcohols and carboxylic acids prior to absorption, or in the liver following 
absorption. 
In general, short chain (< C8) linear and branched-chain aliphatic esters, alcohols, aldehydes and 
carboxylic acids are rapidly absorbed from the gastrointestinal tract. Long-chain carboxylic acids, such 
Flavouring Group Evaluation 06, Revision 2 
 
 
11 EFSA Journal 2011;9(3):1844 
as linoleic acid and oleic acid, are readily absorbed from micelles in the jejunum, re-esterified with 
glycerol in chylomicrons and transported via the lymphatic system.  
In vitro hydrolysis data from studies with esters structurally related to the candidate substances 
indicate that the esters included in this evaluation are hydrolysed to yield the corresponding alcohols 
and carboxylic acids in the gut prior to absorption or in the blood and liver following absorption.  
Candidate alcohols are oxidized to their corresponding carboxylic acids via aldehydes. Candidate 
aldehydes are oxidized to their corresponding carboxylic acids. In general, the carboxylic acids 
included in the present flavouring group or resulting from the hydrolysis of esters or oxidation of 
alcohols and aldehydes are expected to complete their metabolism in the fatty acid pathway or 
tricarboxylic acid cycle. 
Branched-chain carboxylic acids resulting from ester hydrolysis, alcohol or aldehyde oxidation may be 
metabolised via omega- and/or beta-oxidation to yield polar metabolites, which are excreted as such or 
as glucuronic acid conjugates, primarily in the urine. The two terpene alcohols resulting from the 
hydrolysis of four of the candidate esters included in the present flavouring group are expected to 
undergo omega-oxidation and excretion as such or after conjugation with glucuronic acid.  
The hydrolysis of the candidate substance hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] generates 2-
ethylbutyric acid [FL-no: 08.045], which is resistant to beta-oxidation and has shown teratogenic 
potential (see Section 8.3). Although 2-ethylbutyric acid can be further conjugated with glucuronic 
acid or undergo omega-oxidation (see Annex III) the candidate substance [FL-no: 09.884] cannot be 
anticipated to be metabolised to innocuous products. 
Terminal double bonds appear in eleven candidate substances [FL-no: 02.125, 02.138, 02.170, 02.175, 
02.176, 02.201, 05.143, 05.174, 09.612, 09.897 and 09.898]. Of these, six are alcohols [FL-no: 
02.125, 02.138, 02.170, 02.175, 02.176 and 02.201], two are aldehydes [FL-no: 05.143 and 05.174], 
and three are esters [FL-no: 09.612, 09.897 and 09.898]. Although theoretically, these double bonds 
may be oxidised to give reactive epoxides, it is expected that for these candidate substances, the 
metabolism via this pathway is negligible. The terminal double bonds are all present in molecules that 
have alcohol- or aldehyde functions at the end distal from the double bond. The alcohol- and aldehyde 
functions are expected to be readily attacked by oxidation processes, ultimately yielding unsaturated 
carboxylic acids, and also hydrolysis of the esters would yield the unsaturated alcohols. Biochemical 
attack of these carboxylic acids via e.g. beta-oxidation or conjugation with glucuronic acid is expected 
to be much more efficient and rapid than microsomal oxidation. 
In summary, it is generally anticipated that the candidate esters will undergo hydrolysis in the 
gastrointestinal tract, blood and liver to yield their corresponding aliphatic alcohols and carboxylic 
acids. Alcohols and aldehydes are oxidised to the corresponding carboxylic acids. The carboxylic 
acids will proceed their metabolism in the fatty acid pathway, tricarboxylic acid cycle, or undergo 
further oxidation and excretion as such or after glucuronic acid conjugation. Except for one candidate 
substance, hex-3-enyl 2-ethylbutyrate [FL-no: 09.884], all the candidate substances can be anticipated 
to be metabolised to innocuous products. 
A more detailed discussion follows in the Annex III on hydrolysis of linear and branched-chain esters, 
metabolism of linear saturated/unsaturated primary alcohols, aldehydes and carboxylic acids, and 
branched-chain unsaturated primary alcohols, aldehydes and carboxylic acids. 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
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corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the 48 candidate substances from chemical groups 1 and 4 the Procedure 
as outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of the 
substances are summarised in Table 2a. 
Step 1 
All candidate substances are classified according to the decision tree approach by Cramer et al. 
(Cramer et al., 1978) into structural class I, except two ([FL-no: 05.143 and 09.884]), which are 
classified into structural class II. 
Step 2 
Step 2 requires consideration of the metabolism of the candidate substances.  
All candidate substances but one are expected to be metabolised into innocuous products. The one 
remaining substance, hex-3-enyl 2-ethylbutyrate [FL-no: 09.884], will be hydrolysed to give 2-
ethylbutyric acid [FL-no: 08.045], which showed teratogenic potential in one mouse subcutaneous 
single-dose study, and is structurally related to valproic acid, which is a known teratogen (see Section 
8.3). 
Accordingly, except for [FL-no: 09.884], all other flavouring substances (i.e. 47 substances) in the 
present flavouring group proceed via the A-side of the Procedure scheme (Annex I). 
The candidate substance [FL-no: 09.884] can, after hydrolysis, generate a potential teratogenic 
metabolite (2-ethylbutyric acid). Although this hydrolysis product is expected to be metabolised e.g. 
via conjugation with glucuronic acid or omega oxidation, it cannot be excluded that adverse effects 
might be elicited, and therefore [FL-no: 09.884] proceeds via the B-side of the Procedure scheme 
(Annex I). 
Step A3 
Forty-six  of the 47 candidate substances proceeding via the A-side have been assigned to structural 
class I and have estimated European daily per capita intakes (MSDI) ranging from 0.001 to 120 
microgram (Table 2a). These intakes are below the threshold of concern of 1800 
microgram/person/day for structural class I. 
One of these 47 candidate substances proceeding via the A-side, [FL-no: 05.143], has been assigned to 
structural class II and has an estimated European daily per capita intake (MSDI) of 0.1 microgram 
(Table 2a). This intake is below the threshold of concern of 540 microgram/person/day for structural 
class II. 
For these 47 candidate substances the conditions of use do not result in an intake greater than the 
threshold of concern for the respective structural classes. 
Based on results of the safety evaluation sequence these 47 candidate substances proceeding via the A-
side of the Procedure do not pose a safety concern when used as flavouring substances at estimated 
levels of intake, based on the MSDI approach. 
Step B3 
This step is only relevant for [FL-no: 09.884] for which the estimated European daily per capita 
Intake (MSDI) is 0.58 microgram, which is far less than the threshold of concern for its structural class 
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(i.e. 540 microgram/person/day for class II). Accordingly, this candidate substance proceed to step B4 
of the Procedure. 
Step B4 
The teratogenic activity of 2-ethylbutyric acid, a hydrolysis product of hex-3-enyl 2-ethylbutyrate 
[FL-no: 09.884], has been described in a single-dose study after subcutaneous administration of 600 
mg/kg body weight (bw) of 2-ethylbutyric acid to pregnant mice. Further, it should be taken into 
account that 2-ethylbutyric acid is structurally related to valproic acid, which is a well-known 
teratogen. 
In a study in which 2-ethylbutyric acid was administered by gavage to pregnant rats once daily on 
gestation days 6 to 15, at dose levels of 0, 150, or 200 mg/kg bw/day, a NOAEL of 200 mg/kg bw/day 
for the teratogenic activity of 2-ethylbutyric acid could be derived.  
The estimated daily per capita intake (MSDI) of the candidate substance is 0.58 microgram 
corresponding to approximately 0.005 microgram 2-ethylbutyric acid/kg bw/day at a body weight of 
60 kg. This intake is more than 4 x 107 lower than the NOAEL for teratogenicity. 
Based on the results of the safety evaluation sequence (Annex I) this candidate substance [FL-no: 
09.884] does not pose a safety concern, including for teratogenicity, at the estimated level of intake, 
based on the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for 45 of the candidate substances in structural class I based on the mTAMDI 
range from 36 to 40000 microgram/person/day. For nine of the substances [FL-no: 05.061, 05.082, 
05.174, 05.203, 05.217, 05.218, 05.220, 09.937 and 09.939] the mTAMDI is below the threshold of 
concern of 1800 microgram/person/day. For 36 of the candidate substances from class I, the mTAMDI 
is above the threshold of concern For one substance [FL-no: 09.674] no information on use levels have 
been provided. For comparison of the intake estimates based on the MSDI approach and the mTAMDI 
approach see Table 6.1. 
The estimated intakes of the two substances [FL-no: 05.143 and 09.884] assigned to structural class II, 
based on the mTAMDI are 1600 and 3900 microgram/person/day, respectively, which is above the 
threshold of concern for structural class II substances of 540 microgram/person/day. For comparison 
of the MSDI- and mTAMDI-values see Table 6.1. 
Thus, for 39 of the 48 candidate substances further information is required. This would include more 
reliable intake data and where required additional toxicity data 
For comparison of the MSDI and mTAMDI values, see Table 6.1 
 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.125 Undec-10-en-1-ol 0.37 3900 Class I 1800 
02.138 Dec-9-en-1-ol 0.15 3900 Class I 1800 
02.152 Hept-3-en-1-ol 0.012 3900 Class I 1800 
02.170 Lavandulol 0.012 3900 Class I 1800 
02.175 2-Methylbut-3-en-1-ol 1.4 3900 Class I 1800 
02.176 3-Methylbut-3-en-1-ol 0.13 3900 Class I 1800 
02.195 Octa-3,5-dien-1-ol 0.061 3900 Class I 1800 
02.201 Pent-4-en-1-ol 0.012 3900 Class I 1800 
02.222 3-Pentenol-1 0.5 3900 Class I 1800 
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02.234 3-Nonen-1-ol 0.011 3900 Class I 1800 
05.061 Oct-6-enal 0.0012 1600 Class I 1800 
05.082 Dodeca-3,6-dienal 0.011 1600 Class I 1800 
05.174 Pent-4-enal 0.11 1600 Class I 1800 
05.203 9-Octadecenal 0.0097 1600 Class I 1800 
05.217 5-Decenal 0.11 1600 Class I 1800 
05.218 16-Octadecenal 0.011 1600 Class I 1800 
05.220 4Z-Dodecenal 1.2 36 Class I 1800 
08.074 Dec-3-enoic acid 0.19 3200 Class I 1800 
08.100 4-Methylpent-3-enoic acid 1.8 3200 Class I 1800 
08.102 Non-3-enoic acid 0.011 3200 Class I 1800 
09.341 Citronellyl hexanoate 0.97 3900 Class I 1800 
09.368 Ethyl 4-methylpent-3-enoate 0.12 3900 Class I 1800 
09.377 Ethyl oct-3-enoate 0.35 3900 Class I 1800 
09.567 Hex-3-enyl decanoate 0.0024 3900 Class I 1800 
09.569 Hex-3-enyl octanoate 0.49 3900 Class I 1800 
09.572 Hex-4-enyl acetate 0.0012 3900 Class I 1800 
09.575 3-Hexenyl heptanoate 0.61 3900 Class I 1800 
09.612 Lavandulyl acetate 0.012 3900 Class I 1800 
09.638 Methyl dec-4-enoate 0.0012 3900 Class I 1800 
09.640 Methyl deca-4,8-dienoate 0.012 3900 Class I 1800 
09.643 Methyl geranate 0.95 3900 Class I 1800 
09.672 Non-3-enyl acetate 0.012 3900 Class I 1800 
09.673 Non-6-enyl acetate 0.12 3900 Class I 1800 
09.674 Nona-3,6-dienyl acetate 0.0024  Class I 1800 
09.831 Ethyl 3,7-dimethyl-2,6-octadienoate 0.61 3900 Class I 1800 
09.838 3-Hexenyl methyl carbonate 0.012 3900 Class I 1800 
09.855 trans-3-Hexenyl hexanoate 0.21 3900 Class I 1800 
09.871 Citronellyl decanoate 0.12 3900 Class I 1800 
09.872 Citronellyl dodecanoate 0.061 3900 Class I 1800 
09.885 Hex-3-enyl hexadecanoate 0.049 3900 Class I 1800 
09.897 3-Methylbut-3-en-1-yl butyrate 0.012 3900 Class I 1800 
09.898 3-Methylbut-3-en-1-yl hexanoate 0.012 3900 Class I 1800 
09.928 trans-3-Hexenyl acetate 1.8 3900 Class I 1800 
09.937 Methyl (3Z)-hexenoate 120 800 Class I 1800 
09.938 6-Methyl-5-hepten-2-yl acetate 1.2 40000 Class I 1800 
09.939 Ethyl (3Z)-hexenoate 120 800 Class I 1800 
05.143 2,5-Dimethyl-2-vinylhex-4-enal 0.12 1600 Class II 540 
09.884 Hex-3-enyl-2-ethylbutyrate 0.58 3900 Class II 540 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual volume of production in Europe (EFFA, 2001e; EFFA, 2002c; 
EFFA, 2006c; EFFA, 2004u; Flavour Industry, 2004a), the combined estimated daily per capita intake 
as flavouring of the 46 candidate substances assigned to structural class I is approximately 255 
microgram, which does not exceed the threshold of concern for the structural class of 1800 
microgram/person/day. 
For the two candidate substances assigned to structural class II the combined estimated daily per 
capita intake is 0.7 microgram, which does not exceed the threshold of concern for structural class II 
of 540 microgram/person/day. 
The candidate substance hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] can be hydrolysed to the 
potential teratogenic substance 2-ethylbutyric acid (and hex-3-en-1-ol). No other candidate substances 
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but one supporting substance, geranyl 2-ethylbutyrate [FL-no: 09.515], can be hydrolysed to 2-
ethylbutyric acid (and geraniol). The estimated combined intake of these two substances corresponds 
to 0.5 microgram 2-ethylbutyric acid/capita/day. This combined intake corresponds to 0.01 microgram 
2-ethylbutyric acid/kg bw/day which is more than 2 x 107 lower than the NOAEL of 200 mg/kg 
bw/day for teratogenicity of 2-ethylbutyric acid in the rat (Narotsky et al., 1994). Therefore, it can be 
concluded that the combined intake of hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] and geranyl 2-
ethylbutyrate [FL-no: 09.515] does not pose a safety concern with respect to teratogenicity when used 
as flavouring substances at their estimated level of intakes, based on the MSDI approach. 
The 48 candidate substances are structurally related to 70 supporting substances evaluated by the 
JEFCA at its 49th, 51st and 61st meeting (JECFA, 1998a; JECFA, 1999a; JECFA, 2004a). The 
production volumes of some of the 70 supporting substances were much higher than for the candidate 
substances. It was noted that the estimated combined intake (in Europe) is approximately 6400 
microgram/capita/day for 65 of the substances, all belonging to structural class I. The estimated levels 
of intake in Europe were not reported for five of the supporting substances [FL-no: 02.110, 08.059, 
09.141, 09.646 and 09.927]. The total combined intake of the candidate and supporting substances is 
6700 microgram/capita/day which exceeds the threshold of concern for a compound belonging to 
structural class I. However, at the level of exposure resulting from the use as flavourings, all the 
candidate and supporting substances are expected to be efficiently metabolised and would not be 
expected to saturate the metabolic pathways. For these reasons and in the light of toxicological data on 
supporting substances (Annex IV), the total combined intake of these substances would not be 
expected to be of safety concern. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for four of the candidate substances and 42 supporting and structurally related 
substances. A few of these flavouring substances have oral LD50 values in mice and rats between 600 
and 3000 mg/kg body weight (bw) but most have LD50 values higher than 5000 mg/kg bw, indicating 
low oral acute toxicity of the candidate substances in the present group. 
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
No subacute, subchronic, chronic nor carcinogenicity studies are available on the candidate 
substances.  
Twelve supporting substances were tested for subacute/subchronic toxicity and/or chronic toxicity, see 
Annex IV, Table IV.2.  
Three mouse carcinogenicity studies were performed with oleic acid [FL-no: 08.013] or oleic 
acid/linoleic acid mixture [FL-no: 08.013/08.041] (El-Khatib & Cora, 1981; Szepsenwol & Boschetti, 
1975; Szepsenwol, 1978) and two carcinogenicity studies were performed with citronellyl 
acetate/geranyl acetate mixture [FL-no: 09.012 / 09.011] in mice and rats (NTP, 1987a).  
The Panel noted the data provided on oleic acid [FL-no: 08.013] as a supporting substance. The former 
EU Scientific Committee on Food allocated in 1991 an ADI “not specified” to fatty acids, including 
oleic acid (CEC, 1991). High intakes of fatty acids may stimulate tumour development in the gastro-
intestinal tract due to promoter activity, which can be considered as a threshold event (Zhang et al., 
1996; Reddy, 1995; Liu et al., 2001; Reddy, 1992). In addition, apart from aneuploidy (threshold 
genotoxic event), no other genotoxic effects with oleic acid were observed. The Panel concludes, that 
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the carcinogenicity of the oleic acid or linoleic acid/oleic acid mixture, if any, is not relevant with 
respect to assessment of the candidate substances in this group.  
A mixture of 29 % citronellyl acetate and 71 % geranyl acetate [FL-no: 09.012/09.011] was tested in 
rats and mice at dose levels of 0, 1000, and 2000 mg/kg bw/day (rats) or 0, 500 and 1000 mg/kg 
bw/day (mice) via gavage (NTP, 1987a). These studies showed an increase of kidney tubular cell 
adenomas in low dose male rats, 2/50 (4 %), but 0/50 in controls and highest dose male rats. For skin 
squamous cell papillomas there was an increase 4/50 (8 %) in low dose male rats, but 0/50 in controls 
and 1/50 in highest dose male rats. The increased tumor incidence was observed in low dose male rats 
and not in mice and in female rats. The authors concluded that “under the conditions of these studies, 
geranyl acetate was not carcinogenic for F344/N rats or B6C3F1 mice of either sex; however,  the 
reduced survival observed in high dose male rats, high dose male mice, and high and low dose female 
mice lowered the sensitivities of these studies for detecting neoplastic responsers in these groups. In 
male rats the marginal increases of squamous cell papillomas of the skin and tubular cell adenomas of 
the kidney may have been related to administration of geranyl acetate” (NTP, 1987a). Further, geranyl 
acetate, the main component of the mixture tested, was not genotoxic in a set of in vitro and in vivo 
tests (see Section 8.4). There were no genotoxicity studies available on citronellyl acetate. The Panel 
concurs the conclusions of the peer reviewed NTP study that geranyl acetate was not carcinogenic. 
Repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
No adequate developmental and reproductive toxicity studies are available for any candidate 
substances for the present flavouring group evaluation (see Table IV.3).  
Two studies on developmental toxicity are available on a hydrolysis product, 2-ethylbutyric acid, of 
the candidate substance hex-3-enyl 2-ethylbutyrate [FL-no: 09.884]. Nau and Loescher (1986) studied 
valproic acid, and a number of metabolites of valproic acid, as well as other related substances 
including 2-ethylbutyric acid [FL-no: 08.045]. The substances were tested with regard to their 
teratogenicity in mouse following single subcutaneous injections of 600 mg/kg on day 8 of gestation. 
Valproic acid as well as 4-en-valproic acid and a number of substances structurally related to valproic 
acid induced neural tube defects with an incidence from 0 % in controls, up to 61 % of live fetuses 
from mice treated with valproic acid (2 % of live fetuses for 2-ethylbutyric acid) (Nau & Löscher, 
1986). The study demonstrates that teratogenicity varies significantly within the group of valproic acid 
metabolites and structurally related substances. 
Narotsky and co-workers (1994) studied the developmental effects of 2-ethylbutyric acid (and other 
aliphatic acids), administered by gavage to pregnant rats (Narotsky et al., 1994). Groups of pregnant 
Sprague-Dawley rats were given 0, 150 or 200 mg/kg bw/day of 2-ethylbutyric acid, on gestation days 
6 to 15. No developmental effects could be demonstrated. 
Developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Experimental data are available for one candidate substance, methyl-3-but-3-en-1-ol [FL-no: 02.176], 
which was not mutagenic in the Ames test.  
There are data from in vitro genotoxicity tests for six supporting substances [FL-no: 05.074, 05.139, 
08.013, 09.011, 09.076, and 09.646]. The most extensively tested substances were oleic acid (six 
studies) and geranyl acetate (12 studies).  
Oleic acid [FL-no: 08.013] gave negative results when tested in in vitro tests for point mutations with 
both bacterial and mammalian cells as well as in a Rec assay. In the absence of exogenous metabolic 
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activation, oleic acid induced chromosomal numerical abnormalities in Chinese hamster V79 cells, but 
no increase in sister-chromatid exchanges (SCE). The increase in chromosomal numerical 
abnormalities, although not dose-dependent, was observed at all concentration levels.  
Geranyl acetate [FL-no: 09.011] was not mutagenic when tested in the Ames test. Negative results 
were also obtained in a Rec assay; moreover, it did not induce unscheduled DNA synthesis (UDS) in 
rat hepatocytes or chromosomal aberration in Chinese hamster ovary (CHO) cells, where it was also 
not able to inhibit DNA synthesis. Geranyl acetate gave weakly positive results in the SCE assay in 
CHO cells, although only at cytotoxic concentrations. In two poorly reported studies, it appeared 
weakly mutagenic at the TK locus in the mouse lymphoma assay in the presence of exogenous 
metabolic activation. In contrast, negative results were obtained in a valid, well-reported study on gene 
mutation at a TK6 locus in human lymphoblasts. 
All the remaining in vitro genotoxicity studies, performed with different supporting substances, gave 
negative results. 
The genotoxic potential of geranyl acetate [FL-no: 09.011] was assessed also in vivo: negative results 
were obtained in a micronucleus test in mice and in UDS induction in rats. Negative data on in vivo 
genotoxicity were also available for another supporting substance 2,6-dimethyl-5-heptanal [FL-no: 
05.074]. 
In summary, the validity of the weak positive results from the gene mutation assay performed with 
geranyl acetate is questionable, taking into account the negative results from other in vitro and in vivo 
assays. The reported induction of aneuploidy by oleic acid can be considered as a threshold event. All 
the remaining genotoxicity tests on supporting substances gave negative results. Data are available for 
one candidate substance, methyl-3-but-3-en-1-ol, which was not mutagenic in the Ames test. On this 
basis and on the results on supporting substances it can be concluded that genotoxicity is not of 
concern for the candidate substances in this FGE. 
Genotoxicity data are summaries in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The 48  candidate substances are straight- and branched-chain unsaturated primary alcohols, 
aldehydes, carboxylic acids or esters and belong to chemical groups 1 or 4.  
Eight of the 48  flavouring substances possess a chiral centre [FL-no: 02.170, 02.175, 05.143, 09.341, 
09.612, 09.871, 09.872 and 09.938]. 
Thirty-one of the 48  substances can exist as geometrical isomers [FL-no: 02.152, 02.195, 02.222, 
02.234, 05.061, 05.082, 05.203, 05.217, 05.218, 05.220, 08.074, 08.102, 09.377, 09.567, 09.569, 
09.572, 09.575, 09.638, 09.640, 09.643, 09.672, 09.673, 09.674, 09.831, 09.838, 09.855, 09.884, 
09.885, 09.928, 09.937 and 09.939]. For 13 of these substances [FL-no: 02.152, 02.222, 05.061, 
05.203, 05.218, 08.074, 08.102, 09.377, 09.640, 09.674, 09.831, 09.884, 09.885] no indication has 
been given that one of the possible isomers has preponderance in the commercial flavouring material.  
Forty-six candidate substances are classified into structural class I. The remaining two substances [FL-
no: 05.143 and 09.884] are classified into structural class II. 
Thirty-eight of the flavouring substances in the present group have been reported to occur naturally in 
a wide range of food items. 
According to the default MSDI approach, the 48  flavouring substances in this group have intakes in 
Europe from 0.001 to 120 microgram/capita/day, which are below the thresholds of concern value for 
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both structural class I (1800 microgram/person/day) and structural class II (540 
microgram/person/day) substances.  
On the basis of the reported annual production volumes in Europe (MSDI approach), the combined 
intake of the 46 candidate substances belonging to structural class I and of the two candidate 
substances belonging to structural class II would result in a total intake of approximately 255 and 0.7 
microgram/capita/day, respectively. These values are below the thresholds of concern for structural 
class I and class II substances of 1800 and 540 microgram/person/day, respectively. The total 
combined estimated intake of 65 of the 70 supporting substances for which European annual 
production data are available and of the 46 candidate substances from structural class I is 
approximately 6700 microgram/capita/day, which exceeds the threshold of concern for structural class 
I (1800 microgram/person/day). However, the substances are expected to be efficiently metabolised 
and are not expected to saturate the metabolic pathways. 
For the substances in this group the limited data available do not give rise to safety concern with 
respect to genotoxicity and carcinogenicity.  
Except for hex-3-enyl 2-ethylbutyrate [FL-no: 09.884] the candidate substances are expected to be 
metabolised to innocuous substances at the estimated levels of use as flavouring substances. One of 
the hydrolysis products of [FL-no: 09.884], 2-ethylbutyric acid, showed teratogenic potential in one 
mouse subcutaneous single-dose study, and is structurally related to valproic acid, which is a known 
teratogen. However, an additional study in which 2-ethylbutyric acid was given by gavage to pregnant 
rats showed a NOAEL of 200 mg/kg bw/day of 2-ethylbutyric acid. This dose is more than 4 x 107 
times higher than the MSDI for 2-ethylbutyric acid arising from the intake of the candidate substance, 
[FL-no: 09.884]. Accordingly, the candidate substance [FL-no: 09.884] does not pose a safety concern 
with respect to teratogenicity when used at the level of intake as flavouring substance estimated on the 
basis of the MSDI approach. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that on the basis of the default MSDI approach these 48 candidate substances would 
not give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances. 
When the estimated intakes were based on the mTAMDI approach they ranged from 36 to 40000 
microgram/person/day for the 45 flavouring substances from structural class I for which data have 
been provided. Thus, the intakes were all above the threshold of concern for structural class I of 1800 
microgram/person/day, except for nine flavouring substances [FL-no: 05.061, 05.082, 05.174, 05.203, 
05.217, 05.218, 05.220, 09.937 and 09.939]. The estimated intakes of the two flavouring substances 
assigned to structural class II, based on the mTAMDI are 1600 and 3900 microgram/person/day, 
which is above the threshold of concern for structural class II of 540 microgram/person/day. The nine 
substances [FL-no: 05.061, 05.082, 05.174, 05.203, 05.217, 05.218, 05.220, 09.937 and 09.939], 
which have mTAMDI intake estimates below the threshold of concern for structural class I, are also 
expected to be metabolised to innocuous products.  
Thus, for 38 of the 48 flavouring substances considered in this Opinion, the intakes, estimated on the 
basis of the mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring 
substance has been assigned. For one substance [FL-no: 09.647] no use levels were provided. 
Therefore, for these 39 substances more reliable exposure data are required. On the basis of such 
additional data, these flavouring substances should be reconsidered along the steps of the Procedure. 
Subsequently, additional data might become necessary.  
In order to determine whether the conclusion for the 48 candidate substances can be applied to the 
material of commerce, it is necessary to consider the available specifications. Adequate specifications 
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including complete purity criteria and identity for the materials of commerce have been provided for 
46 of the 48 flavouring candidate substances. An ID test is missing for [FL-no: 09.938] and a boiling 
point is lacking for [FL-no: 09.674]. Otherwise the specifications are adequate for all 48 candidate 
substances, except that information on composition of stereoisomeric mixture has not been specified 
sufficiently for 13 of the substances [FL-no: 02.152, 02.222, 05.061, 05.203, 05.218, 08.074, 08.102, 
09.377, 09.640, 09.674, 09.831, 09.884 and 09.885].  
Thus, the final evaluation of the materials of commerce cannot be performed for 14 substances [FL-
no: 02.152, 02.222, 05.061, 05.203, 05.218, 08.074, 08.102, 09.377, 09.640, 09.674, 09.831, 09.884, 
09.885 and 09.938], pending further information. The remaining 34 substances [FL-no: 02.125, 
02.138, 02.170, 02.175, 02.176, 02.195, 02.201, 02.234, 05.082, 05.143, 05.174, 05.217, 05.220, 
08.100, 09.341, 09.368, 09.567, 09.569, 09.572, 09.575, 09.612, 09.638, 09.643, 09.672, 09.673, 
09.838, 09.855, 09.871, 09.872, 09.897, 09.898, 09.928, 09.937 and 09.939] would present no safety 
concern at the levels of intake estimated on the basis of the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 06 REVISION 2 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 06 Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.125 
 
Undec-10-en-1-ol OH   
10319 
112-43-6 
Liquid 
C11H22O 
170.29 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
245-248 
 
MS 
95 % 
1.445-1.451 
0.845-0.851 
 
 
02.138 
 
Dec-9-en-1-ol OH   
 
13019-22-2 
Liquid 
C10H20O 
156.27 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
86 (3 hPa) 
 
MS 
95 % 
1.445-1.451 
0.842-0.848 
 
 
02.152 
 
Hept-3-en-1-ol OH
(E)-isomer shown  
 
10219 
10606-47-0 
Liquid 
C7H14O 
114.19 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
80 (27 hPa) 
 
MS 
95 % 
1.439-1.445 
0.848-0.854 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
02.170 
 
Lavandulol 
OH
 
 
498-16-8 
Liquid 
C10H18O 
154.25 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
78 (7 hPa) 
 
MS 
95 % 
1.467-1.473 
0.877-0.883 
 
Register name to be changed 
to (R)-(-)-Lavandulol. 
02.175 
 
2-Methylbut-3-en-1-ol OH
 
 
10259 
4516-90-9 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
1 ml in 1 ml 
122 
 
MS 
95 % 
1.421-1.427 
0.841-0.847 
 
Racemate. 
02.176 
 
3-Methylbut-3-en-1-ol OH
 
 
10260 
763-32-6 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
1 ml in 1 ml 
130 
 
MS 
95 % 
1.431-1.437 
0.850-0.856 
 
 
02.195 
 
Octa-3,5-dien-1-ol OH   
 
70664-96-9 
Liquid 
C8H14O 
126.20 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
90 (24 hPa) 
 
NMR 
95 % 
1.457-1.463 
0.865-0.871 
 
Register name to be changed 
to Octa-(3Z,5E)-dien-1-ol. 
02.201 
 
Pent-4-en-1-ol OH   
 
821-09-0 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
1 ml in 1 ml 
137 
 
MS 
95 % 
1.427-1.433 
0.843-0.849 
 
 
02.222 
 
3-Pentenol-1 OH
E-isomer shown  
 
10298 
39161-19-8 
Liquid 
C5H10O 
86.13 
Sparingly soluble 
1 ml in 1 ml 
134 
 
MS 
95 % 
1.432-1.438 
0.846-0.852 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 06 Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.234 
 
3-Nonen-1-ol OH  4412 
10293 
10340-23-5 
Liquid 
C9H18O 
142.24 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
115 (33 hPa) 
 
MS 
95 % 
1.452-1.458 
0.862-0.868 
 
Register name to be changed 
to (3Z)-Nonen-1-ol (EFFA, 
2010a). 
 
05.061 
 
Oct-6-enal O
(E)- isomer shown  
 
664 
63826-25-5 
Liquid 
C8H14O 
126.20 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
87 (67 hPa) 
 
NMR 
95 % 
1.433-1.439 
0.842-0.848 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
05.082 
 
Dodeca-3,6-dienal O   
2121 
13553-09-8 
Liquid 
C12H20O 
180.24 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
226 
 
MS 
95 % 
1.440-1.446 
0.844-0.850 
 
Register name to be changed 
to Dodeca-(3Z,6Z)-dienal 
(EFFA, 2010a). 
 
05.143 
 
2,5-Dimethyl-2-vinylhex-4-enal O
 
 
 
56134-05-5 
Liquid 
C10H16O 
152.24 
Sparingly soluble 
1 ml in 1 ml 
72 (16 hPa) 
 
MS 
95 % 
1.452-1.458 
0.845-0.851 
 
Racemate (EFFA, 2010a). 
05.174 
1619 
Pent-4-enal O   
 
2100-17-6 
Liquid 
C5H8O 
84.12 
Slightly soluble 
1 ml in 1 ml 
103 
 
MS 
95 % 
1.413-1.420 
0.849-0.855 
 
 
05.203 
1641 
9-Octadecenal O   
 
5090-41-5 
Liquid 
C18H34O 
266.47 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
168 (5 hPa) 
 
MS 
95 % 
1.455-1.461 
0.848-0.854 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
05.217 
 
5-Decenal O   
 
21662-08-8 
Liquid 
C10H18O 
154.25 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
92 (3 hPa) 
 
MS 
95 % 
1.441-1.447 
0.842-0.848 
 
Register name to be changed 
to (5Z)-Decenal (EFFA, 
2010a). 
 
05.218 
 
16-Octadecenal 
O  
 
 
56554-87-1 
Solid 
C18H34O 
266.46 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
391 
56 
MS 
95 % 
n.a. 
n.a. 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
05.220 
1636 
4Z-Dodecenal 
O  4036 
 
21944-98-9 
Liquid 
C12H22O 
182.30 
Slightly soluble 
Very soluble 
254 
n.a. 
IR NMR MS 
1.443-1.449 
0.843-0.849 
 
Known imputities: 1.06 % 
4E-dodecenal, 3.66 % 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 06 Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
94 % dodecanal (FL-no: 05.011), 
1.29 % tetradecane (FL-no: 
01.057). 
08.074 
 
Dec-3-enoic acid 
OH
O
E-isomer shown  
 
10088 
15469-77-9 
Liquid 
C10H18O2 
170.25 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
158 
 
MS 
95 % 
1.437-1.457 
0.933-0.939 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
08.100 
 
4-Methylpent-3-enoic acid 
OH
O
 
 
 
504-85-8 
Liquid 
C6H10O2 
114.14 
Sparingly soluble 
1 ml in 1 ml 
99 (13 hPa) 
 
MS 
95 % 
1.443-1.449 
0.973-0.979 
 
 
08.102 
 
Non-3-enoic acid 
O
OH
 
 
10154 
4124-88-3 
Liquid 
 
156.22 
Very slightly soluble 
1 ml in 1 ml 
158 (24 hPa) 
 
MS 
95 % 
1.445-1.451 
0.925-.0931 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
09.341 
 
Citronellyl hexanoate 
O
O
 
 
 
10580-25-3 
Liquid 
C16H30O2 
254.41 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
240 
 
MS 
95 % 
1.446-1.450 
0.871-0.876 
 
Racemate (EFFA, 2010a). 
09.368 
 
Ethyl 4-methylpent-3-enoate 
O
O
 
 
10615 
6849-18-9 
Liquid 
C8H14O2 
142.20 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
66 (23 hPa) 
 
MS 
95 % 
1.427-1.433 
0.910-0.916 
 
 
09.377 
1632 
Ethyl oct-3-enoate 
O
O
E-isomer shown  
4361 
10618 
1117-65-3 
Liquid 
C10H18O2 
170.25 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
94 (13 hPa) 
 
MS 
95 % 
1.431-1.439 
0.903-0.910 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
09.567 
 
Hex-3-enyl decanoate 
O
O
 
 
 
85554-69-4 
Liquid 
C16H30O2 
254.41 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
315 
 
MS 
95 % 
1.439-1.445 
0.875-0.881 
 
Register name to be changed 
to Hex-(3Z)-enyl decanoate. 
09.569 
 
Hex-3-enyl octanoate 
O
O
 
 
 
61444-41-5 
Liquid 
C14H26O2 
226.36 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
286 
 
MS 
95 % 
1.431-1.451 
0.878-0.884 
 
Register name to be changed 
to Hex-(3Z)-enyl octanoate. 
09.572 
 
Hex-4-enyl acetate 
O
O
 
 
 
42125-17-7 
Liquid 
C8H14O2 
142.20 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
73 (27 hPa) 
 
MS 
1.426-1.432 
0.900-0.906 
 
Register name to be changed 
to Hex-(4Z)-enyl acetate. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 06 Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
95 % 
09.575 
 
3-Hexenyl heptanoate 
O
O
 
 
 
61444-39-1 
Liquid 
C13H24O2 
212.33 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
270 
 
MS 
95 % 
1.433-1.439 
0.880-0.886 
 
Register name to be changed 
to (3Z)-Hexenyl heptanoate. 
09.612 
 
Lavandulyl acetate 
O
O
 
 
25905-14-0 
Liquid 
C12H20O2 
196.29 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
100 (15 hPa) 
 
MS 
95 % 
1.453-1.459 
0.909-0.915 
 
Racemate (EFFA, 2010a). 
09.638 
 
Methyl dec-4-enoate 
O
O
 
 
10784 
7367-83-1 
Liquid 
C11H20O2 
184.28 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
112 (20 hPa) 
 
MS 
95 % 
1.438-1.444 
0.891-0.897 
 
Register name to be changed 
to Methyl dec-(4Z)-enoate. 
09.640 
 
Methyl deca-4,8-dienoate 
O
O
(4E, 8E)-isomer shown  
 
10782 
1191-03-3 
Liquid 
C11H18O2 
182.26 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
241 
 
NMR 
95 % 
1.443-1.449 
0.904-0.910 
 
Mixture of 
(E,E)/(E,Z)/(Z,E)/(Z,Z) 
(EFFA, 2010a).  
Composition of 
stereoisomeric mixture to be 
specified. 
09.643 
 
Methyl geranate O
O
 
10797 
1189-09-9 
Liquid 
C11H18O2 
182.26 
Insoluble 
1 ml in 1 ml 
97 (13 hPa) 
 
MS 
95 % 
1.465-1.471 
0.916-0.925 
 
 
09.672 
 
Non-3-enyl acetate 
O
O
 
 
 
13049-88-2 
Liquid 
C11H20O2 
184.28 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
61 (0.1 hPa) 
 
MS 
95 % 
1.429-1.435 
0.886-0.892 
 
Register name to be changed 
to Non-(3Z)-enyl acetate. 
09.673 
 
Non-6-enyl acetate 
O
O
 
 
 
76238-22-7 
Liquid 
C11H20O2 
184.28 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
90 (4 hPa) 
 
MS 
95 % 
1.432-1.438 
0.886-0.892 
 
Register name to be changed 
to Non-(6Z)-enyl acetate. 
09.674 
 
Nona-3,6-dienyl acetate   6) 
O
O
 
 
 
76649-26-8 
Liquid 
C11H18O2 
182.26 
Insoluble 
Soluble 
 
 
MS 
98% 
1.4410-
1.4610 
0.890-0.910 
BP 7). 
(Z)- or (E)-isomer not 
specified by CASrn in 
Register. 
09.831 
 
Ethyl 3,7-dimethyl-2,6-
octadienoate 
O
O
E-isomer shown
 
 
13058-12-3 
Liquid 
C12H20O2 
196.29 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
114 (13 hPa) 
 
MS 
95 % 
1.463-1.469 
0.911-0.917 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 06 Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
09.838 
 
3-Hexenyl methyl carbonate 
O O
O
 
 
 
67633-96-9 
Liquid 
C8H14O3 
158.19 
Slightly soluble 
1 ml in 1 ml 
78 (4 hPa) 
 
MS 
98 % 
1.426-1.430 
0.966-0.971 
 
Register name to be changed 
(3Z)-Hexenyl methyl 
carbonate. 
09.855 
 
trans-3-Hexenyl hexanoate 
O
O
 
 
 
56922-82-8 
Liquid 
C12H22O2 
198.30 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
253 
 
MS 
95 % 
1.428-1.434 
0.883-0.889 
 
 
09.871 
 
Citronellyl decanoate 
O
O
 
 
 
72934-06-6 
Liquid 
C20H38O2 
310.52 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
202 (13 hPa) 
 
NMR 
95 % 
1.448-1.454 
0.869-0.875 
 
Racemate (EFFA, 2010a). 
09.872 
 
Citronellyl dodecanoate 
O
O
 
 
 
72934-07-7 
Liquid 
C22H42O2 
338.57 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
217 (13 hPa) 
 
NMR 
95 % 
1.450-1.456 
0.867-0.873 
 
Racemate (EFFA, 2010a). 
09.884 
 
Hex-3-enyl-2-ethylbutyrate 
O
O
E-isomer shown  
 
 
233666-04-1 
Liquid 
C12H22O2 
198.30 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
243 
 
NMR 
95 % 
1.426-1.432 
0.881-0.887 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
09.885 
 
Hex-3-enyl hexadecanoate 
O
O
E-isomer shown
 
 
233666-03-0 
Liquid 
C22H42O2 
338.57 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
387 
 
NMR 
95 % 
1.454-1.460 
0.867-0.873 
 
Mixture of (Z)- and (E)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
09.897 
 
3-Methylbut-3-en-1-yl butyrate 
O
O
 
 
 
54702-13-5 
Liquid 
C9H16O2 
156.22 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
184 
 
MS 
95 % 
1.439-1.445 
0.886-0.892 
 
 
09.898 
 
3-Methylbut-3-en-1-yl hexanoate 
O
O
 
 
 
53655-22-4 
Liquid 
C11H20O2 
184.28 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
223 
 
MS 
95 % 
1.453-1.458 
0.877-0.883 
 
 
09.928 
 
trans-3-Hexenyl acetate O
O  
4413 
 
3681-82-1 
Liquid 
C8H14O2 
142.20 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
201 
 
MS 
97 % 
1.420-1.426 
0.893-0.899 
 
 
09.937 
1624 
Methyl (3Z)-hexenoate 
O
O
 
 
 
13894-62-7 
Liquid 
C7H12O2 
128.17 
Sparingly soluble 
Soluble 
85 (107 hPa) 
 
MS 
> 95 % 
1.422-1.430 
0.914-0.924 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 06 Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
09.938 
1838 
6-Methyl-5-hepten-2-yl acetate O
O  
4177 
 
19162-00-6 
Liquid 
C10H18O2 
170.25 
Insoluble 
Soluble 
184 
 
 
> 97 % 
1.420-1.429 
0.893-0.903 
ID 8). 
Racemate (EFFA, 2010a). 
09.939 
1626 
Ethyl (3Z)-hexenoate 
O
O
 
 
 
64187-83-3 
Liquid 
C8H14O2 
142.20 
Sparingly soluble 
Soluble 
90 (67 hPa) 
 
MS 
> 96 % 
1.420-1.429 
0.893-0.903 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
7) BP: Missing boiling point. 
8) ID: Missing identification test. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.125 
 
Undec-10-en-1-ol OH  0.37 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.138 
 
Dec-9-en-1-ol OH  0.15 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.152 
 
Hept-3-en-1-ol OH
(E)-isomer shown
0.012 
 
Class I 
A3: Intake below threshold 
4) 7)  
02.170 
 
Lavandulol 
OH
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.175 
 
2-Methylbut-3-en-1-ol OH 1.4 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.176 
 
3-Methylbut-3-en-1-ol OH 0.13 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.195 
 
Octa-3,5-dien-1-ol OH  0.061 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.201 
 
Pent-4-en-1-ol OH  0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.222 
 
3-Pentenol-1 OH
E-isomer shown
0.5 
 
Class I 
A3: Intake below threshold 
4) 7)  
02.234 
 
3-Nonen-1-ol OH  0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.061 
 
Oct-6-enal O
(E)- isomer shown
0.0012 
 
Class I 
A3: Intake below threshold 
4) 7)  
05.082 
 
Dodeca-3,6-dienal O  0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.174 
1619 
Pent-4-enal O  0.11 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.203 
1641 
9-Octadecenal O  0.0097 
 
Class I 
A3: Intake below threshold 
4) 7)  
05.217 
 
5-Decenal O  0.11 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.218 
 
16-Octadecenal 
O
0.011 
 
Class I 
A3: Intake below threshold 
4) 7)  
05.220 
1636 
4Z-Dodecenal 
O  1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.074 
 
Dec-3-enoic acid 
OH
O
E-isomer shown
0.19 
 
Class I 
A3: Intake below threshold 
4) 7)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
08.100 
 
4-Methylpent-3-enoic acid 
OH
O 1.8 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.102 
 
Non-3-enoic acid 
O
OH 0.011 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.341 
 
Citronellyl hexanoate 
O
O 0.97 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.368 
 
Ethyl 4-methylpent-3-enoate 
O
O 0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.377 
1632 
Ethyl oct-3-enoate 
O
O
E-isomer shown
0.35 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.567 
 
Hex-3-enyl decanoate 
O
O 0.0024 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.569 
 
Hex-3-enyl octanoate 
O
O 0.49 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.572 
 
Hex-4-enyl acetate 
O
O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.575 
 
3-Hexenyl heptanoate 
O
O 0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.612 
 
Lavandulyl acetate 
O
O
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.638 
 
Methyl dec-4-enoate 
O
O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.640 
 
Methyl deca-4,8-dienoate 
O
O
(4E, 8E)-isomer shown
0.012 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.643 
 
Methyl geranate O
O
0.95 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.672 
 
Non-3-enyl acetate 
O
O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.673 
 
Non-6-enyl acetate 
O
O 0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
09.674 
 
Nona-3,6-dienyl acetate 
O
O 0.0024 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.831 
 
Ethyl 3,7-dimethyl-2,6-
octadienoate 
O
O
E-isomer shown
0.61 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.838 
 
3-Hexenyl methyl carbonate 
O O
O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.855 
 
trans-3-Hexenyl hexanoate 
O
O 0.21 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.871 
 
Citronellyl decanoate 
O
O 0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.872 
 
Citronellyl dodecanoate 
O
O 0.061 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.885 
 
Hex-3-enyl hexadecanoate 
O
O
E-isomer shown
0.049 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.897 
 
3-Methylbut-3-en-1-yl butyrate 
O
O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.898 
 
3-Methylbut-3-en-1-yl hexanoate 
O
O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.928 
 
trans-3-Hexenyl acetate O
O  
1.8 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.937 
1624 
Methyl (3Z)-hexenoate 
O
O 120 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.938 
1838 
6-Methyl-5-hepten-2-yl acetate O
O
1.2 
 
Class I 
A3: Intake below threshold 
4) 7)  
09.939 
1626 
Ethyl (3Z)-hexenoate 
O
O 120 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.143 
 
2,5-Dimethyl-2-vinylhex-4-enal O 0.12 
 
Class II 
A3: Intake below threshold 
4) 6)  
09.884 
 
Hex-3-enyl-2-ethylbutyrate 
O
O
E-isomer shown
0.58 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 7)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day , Class II = 540 µg/person/day , Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
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4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 Methanol 
CH4O 
32.04 
H
H
H
OH
 
Not evaluated as flavouring substance  Not in EU-Register 
 Hex-3(trans)-en-1-ol OH  Not evaluated as flavouring substance  
 
 
Not in EU-Register (former [FL-no: 
02.158] 
 3,6 Nonadienol HO  Not evaluated as flavouring substance  Not in EU-Register 
 Hex-(3Z)-enoic acid 
OHO  
Not evaluated as flavouring substance  Not in EU-Register 
 Oct-3-enoic acid 
OH
O
 
Not evaluated as flavouring substance  
 
 
Not in EU-Register (former [FL-no: 
08.105] 
 Deca-4,8-dienoic acid O
HO
Not evaluated as flavouring substance  Not in EU-Register 
02.011 Citronellol 
1219 OH  
 
No safety concern a) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
02.056 Hex-3(cis)-en-1-ol 
315 
OH  Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: Not 
endogenous, A5: Adequate NOAEL exists 
 
02.074 Hex-4-en-1-ol 
318 
OH
(E)-isomer shown  
Category 2 c) 
No safety concern d) 
Category B b) 
 
Class I 
A3: Intake below threshold 
 
02.078 Ethanol 
41 
OH  Category 1 c) 
No safety concern e) 
 
 
 
No evaluation 
At the forty-sixth JECFA meeting (JECFA, 
1997a), the Committee concluded that 
ethanol posed no safety concern at its 
current level of intake when ethyl esters are 
used as flavouring agents. 
02.093 Non-6-en-1-ol 
324 
OH   
No safety concern d) 
 
 
Class I 
A3: Intake below threshold 
 
02.124 6-Methylhept-5-en-2-ol 
 
OH
 
Category 2 c) 
 
 
Class I 
A3: Intake below threshold 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
FGE.07 
02.159 Hex-3-en-1-ol 
315 
OH   
 
Category A b) 
 
 
No evaluation 
 
02.170 Lavandulol 
 
OH
 
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
02.176 3-Methylbut-3-en-1-ol 
 
OH
 
 
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
02.234 3-Nonen-1-ol 
 
OH   
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
08.002 Acetic acid 
81 
O
OH  
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.005 Butyric acid 
87 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.009 Hexanoic acid 
93 
O
OH  
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.010 Octanoic acid 
99 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.011 Decanoic acid 
105 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.012 Dodecanoic acid 
111 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.014 Hexadecanoic acid 
115 
OH
O
 
Category 1 c) 
No safety concern f) 
Deleted b) 
 
Class I 
A3: Intake below threshold 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
08.028 Heptanoic acid 
96 
OH
O
 
Category 1 c) 
No safety concern f) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.045 2-Ethylbutyric acid 
257 
OH
O
 
Category 1 c) 
No safety concern f) 
Category B b) 
 
Class II 
A3: Intake below threshold 
 
08.075 Dec-4-enoic acid 
1287 
OH
O
(E)-isomer shown  
 
No safety concern a) 
 
 
Class I 
A3: Intake below threshold 
 
08.081 Geranic acid 
1825 
OH
O
 
 
 
 
 
Class I 
A3: Intake below threshold 
 
08.100 4-Methylpent-3-enoic acid 
 
OH
O
 
 
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day , Class II = 540 µg/person/day , Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2004a). 
b) (CoE, 1992). 
c) (SCF, 1995). 
d) (JECFA, 2000a). 
e) (JECFA, 1997a). 
f) (JECFA, 1999b). 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.056 Hex-3(cis)-en-1-ol OH  2563 
750c 
928-96-1 
315 
JECFA specification (JECFA, 
1998b) 
3700 Category 1 a) 
No safety concern b) 
Category A c) 
 
02.074 Hex-4-en-1-ol OH
(E)-isomer shown  
3430 
2295 
6126-50-7 
318 
JECFA specification (JECFA, 
1998b) 
2.4 Category 2 a) 
No safety concern b) 
Category B c) 
JECFA evaluated 4-
hexen-1-ol (CASrn as in 
Register). (Z)- or (E)-
isomer not specified by 
CASrn in Register. 
02.093 Non-6-en-1-ol OH  3465 
10294 
35854-86-5 
324 
JECFA specification (JECFA, 
2000d) 
2.2  
No safety concern b) 
 
JECFA evaluated cis-6-
nonen-1-ol (CASrn as in 
Register). CASrn in 
Register refers to (Z)-
isomer. Register name to 
be changed to Non-6Z-
en-1-ol. 
02.094 Oct-3-en-1-ol OH  3467 
10296 
20125-84-2 
321 
JECFA specification (JECFA, 
1998b) 
4.7 Category 2 a) 
No safety concern b) 
 
JECFA evaluated cis-3-
octen-1-ol (CASrn as in 
Register). CASrn in 
Register refers to the 
(Z)-isomer. Register 
name to be changed to 
Oct-3Z-en-1-ol. 
02.110 2,6-Dimethylhept-6-en-1-ol 
OH
 
3663 
 
36806-46-9 
348 
JECFA specification (JECFA, 
2003b) 
ND Category 3 a) 
No safety concern b) 
 
JECFA evaluated 2,6-
dimethyl-6-hepten-1-ol 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by CASrn 
in Register. 
02.113 Oct-5(cis)-en-1-ol OH  3722 
 
64275-73-6 
322 
JECFA specification (JECFA, 
2003b) 
0.4 Category 2 a) 
No safety concern b) 
 
 
05.035 Undec-10-enal O  3095 
122 
112-45-8 
330 
JECFA specification (JECFA, 
2001c) 
0.32  
No safety concern b) 
Category B c) 
 
05.036 Undec-9-enal O
(E)-isomer shown  
3094 
123 
143-14-6 
329 
JECFA specification (JECFA, 
2003b) 
0.97  
No safety concern b) 
Category A c) 
JECFA evaluated 9-
undecenal (CASrn as in 
Register). (Z)- or (E)-
isomer not specified by 
CASrn in Register. 
05.059 Non-6(cis)-enal O  3580 
661 
2277-19-2 
325 
JECFA specification (JECFA, 
2003b) 
1.7  
No safety concern b) 
Category B c) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
05.074 2,6-Dimethylhept-5-enal 
O
 
2389 
2006 
106-72-9 
349 
JECFA specification (JECFA, 
2003b) 
27 Category 1 a) 
No safety concern b) 
Category B c) 
JECFA evaluated 2,6-
dimethyl-5-heptenal 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by CASrn 
in Register. 
05.075 Hex-3(cis)-enal O  2561 
2008 
6789-80-6 
316 
JECFA specification (JECFA, 
2000d) 
4.1  
No safety concern b) 
Category B c) 
 
05.085 Hept-4-enal O
(Z)-isomer shown  
3289 
2124 
6728-31-0 
320 
JECFA specification (JECFA, 
2000d) 
1.6  
No safety concern b) 
Category B c) 
JECFA evaluated 4-
heptenal (CASrn as in 
Register). CASrn in 
Register refers to the 
(Z)-isomer.  
05.096 4-Decenal Ο
(E)-isomer shown  
3264 
2297 
30390-50-2 
326 
JECFA specification (JECFA, 
2001c) 
0.97  
No safety concern b) 
Category B c) 
JECFA evaluated 4-
decenal (CASrn as in 
Register). (Z)- or (E)-
isomer not specified by 
CASrn in Register. 
05.113 Hex-4-enal O  3496 
10337 
4634-89-3 
319 
JECFA specification (JECFA, 
2000d) 
0.024  
No safety concern b) 
 
JECFA evaluated cis-4-
hexenal (CASrn as in 
Register). CASrn in 
Register refers to the 
(Z)-isomer. Register 
name to be changed to 
Hex-4Z-enal. 
05.128 Oct-5(cis)-enal O  3749 
 
41547-22-2 
323 
JECFA specification (JECFA, 
2003b) 
0.0012  
No safety concern b) 
 
 
08.013 Oleic acid 
OH
O
 
2815 
13 
112-80-1 
333 
JECFA specification (JECFA, 
2000d) 
830 Category 1 a) 
No safety concern b) 
Deleted c) 
 
08.039 Undec-10-enoic acid 
OH
O
 
3247 
689 
112-38-9 
331 
JECFA specification (JECFA, 
1998b) 
26 Category 1 a) 
No safety concern b) 
Category A c) 
 
08.041 Octadeca-9,12-dienoic acid 
OH
O
 
3380 
694 
60-33-3 
332 
JECFA specification (JECFA, 
2003b) 
110 Category 1 a) 
No safety concern b) 
Deleted c) 
Register name to be 
changed to Linoleic 
acid. 
08.048 Pent-4-enoic acid 
OH
O
 
2843 
2004 
591-80-0 
314 
JECFA specification (JECFA, 
1998b) 
3.9  
No safety concern b) 
Category B c) 
 
08.050 Hex-3-enoic acid 
OH
O
(E)-isomer shown  
3170 
2256 
4219-24-3 
317 
JECFA specification (JECFA, 
2000d) 
9.4 Category 1 a) 
No safety concern b) 
Category B c) 
JECFA evaluated 3-
hexenoic acid (CASrn as 
in Register). (Z)- or (E)-
isomer not specified by 
CASrn in Register. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
08.058 2-Methylpent-3-enoic acid 
OH
O
(E)-isomer shown  
3464 
10147 
37674-63-8 
347 
JECFA specification (JECFA, 
2001c) 
1.2 Category 1 a) 
No safety concern b) 
 
JECFA evaluated 2-
methyl-3-pentenoic-acid 
(CASrn as in Register). 
(Z)- or (E)-isomer not 
specified by CASrn in 
Register. 
08.059 2-Methylpent-4-enoic acid 
OH
O
 
3511 
10148 
1575-74-2 
355 
JECFA specification (JECFA, 
1998b) 
ND Category N a) 
No safety concern b) 
 
JECFA evaluated 2-
methyl-4-pentenoic-acid 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by CASrn 
in Register. 
08.065 Dec-9-enoic acid 
OH
O
 
3660 
10090 
14436-32-9 
328 
JECFA specification (JECFA, 
2001c) 
0.097 Category 1 a) 
No safety concern b) 
 
 
08.068 Dec-(5- and 6)-enoic acid 
OH
O
OH
O
(E)-isomers shown
3742 
 
72881-27-7 
327 
JECFA specification (JECFA, 
2000d) 
3.4 Category N a) 
No safety concern b) 
 
JECFA evaluated 5 & 6-
decenoic acid (mixture) 
(CASrn as in Register). 
CASrn in Register refers 
to incompletely defined 
substance. 
09.011 Geranyl acetate 
O
O
 
2509 
201 
105-87-3 
58 
JECFA specification (JECFA, 
2001c) 
470  
No safety concern d) 
Category A c) 
GrADI: 0-0.5 (JECFA, 
1980a). 
09.012 Citronellyl acetate 
O
O
 
2311 
202 
150-84-5 
57 
JECFA specification (JECFA, 
2003b). (R) or (S) enatiomer 
not specified by CASrn in 
Register 
190  
No safety concern d) 
Category A c) 
GrADI: 0-0.5 (JECFA, 
1980a). R- or S-
enantiomer not specified 
by CASrn in Register. 
09.033 Rhodinyl acetate 
O
O
 
2981 
223 
141-11-7 
60 
JECFA specification (JECFA, 
2003b) 
0.97  
No safety concern d) 
Deleted c) 
CASrn in Register refers 
to 3,7-dimethyl-7-octen-
1-ol-1-acetate; (R)- or 
(S)-enantiomer not 
specified by CASrn in 
Register. Register name 
corresponds to CASrn 
9448-73-9; which is the 
(S)-enantiomer. 
09.048 Geranyl butyrate 
O
O
 
2512 
274 
106-29-6 
66 
JECFA specification (JECFA, 
2003b) 
52  
No safety concern d) 
Category A c) 
 
09.049 Citronellyl butyrate 
OO
2312 
275 
141-16-2 
65 
JECFA specification (JECFA, 
2003b) 
27  
No safety concern d) 
Category A c) 
R- or S-enantiomer not 
specified by CASrn in 
Register. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.067 Geranyl hexanoate O
O  
2515 
317 
10032-02-7 
70 
JECFA specification (JECFA, 
2001c) 
0.061  
No safety concern d) 
Category A c) 
 
09.076 Geranyl formate 
OO  
2514 
343 
105-86-2 
54 
JECFA specification (JECFA, 
2003b) 
280  
No safety concern d) 
Category A c) 
 
09.078 Citronellyl formate 
O O  
2314 
345 
105-85-1 
53 
JECFA specification (JECFA, 
2005b) 
87  
No safety concern d) 
Category A c) 
GrADI: 0-0.5 (JECFA, 
1980a). R- or S-
enantiomer not specified 
by CASrn in Register. 
09.079 Rhodinyl formate 
O
O
 
2984 
346 
141-09-3 
56 
JECFA specification (JECFA, 
2003b) 
0.061  
No safety concern d) 
Deleted c) 
R- or S-enantiomer not 
specified by CASrn in 
Register. 
09.128 Geranyl propionate 
O
O
 
2517 
409 
105-90-8 
62 
JECFA specification (JECFA, 
2003b) 
69  
No safety concern d) 
Category A c) 
 
09.129 Citronellyl propionate O
O  
2316 
410 
141-14-0 
61 
JECFA specification (JECFA, 
2003b) 
35  
No safety concern d) 
Category A c) 
R- or S-enantiomer not 
specified by CASrn in 
Register. 
09.141 Rhodinyl propionate 
O
O
2986 
422 
105-89-5 
64 
JECFA specification (JECFA, 
2001c) 
ND  
No safety concern d) 
Deleted c) 
R- or S-enantiomer not 
specified by CASrn in 
Register. 
09.151 Citronellyl valerate 
O
O
 
2317 
469 
7540-53-6 
69 
JECFA specification (JECFA, 
2000d) 
0.61  
No safety concern d) 
Category A c) 
R- or S-enantiomer not 
specified by CASrn in 
Register. 
09.167 Neryl butyrate 
O
O
2774 
505 
999-40-6 
67 
JECFA specification (JECFA, 
1997b) 
0.35  
No safety concern d) 
Category B c) 
 
09.169 Neryl propionate 
O
O
2777 
509 
105-91-9 
63 
JECFA specification (JECFA, 
1997b) 
3.7  
No safety concern d) 
Category B c) 
 
09.191 Ethyl hex-3-enoate 
O
O
(Z)-isomer shown  
3342 
 
2396-83-0 
335 
JECFA specification (JECFA, 
1998b) 
3.2  
No safety concern b) 
 
JECFA evaluated ethyl-
3-hexenoate (CASrn as 
in Register). (Z)- or (E)-
isomer not specified by 
CASrn in Register. 
09.192 Ethyl oleate 
O
O
 
2450 
633 
111-62-6 
345 
JECFA specification (JECFA, 
1998b) 
60  
No safety concern b) 
Category A c) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.212 Neryl formate 
O
O
2776 
2060 
2142-94-1 
55 
JECFA specification (JECFA, 
2005b) 
0.0061  
No safety concern d) 
Category B c) 
 
09.213 Neryl acetate 
O
O
2773 
2061 
141-12-8 
59 
JECFA specification (JECFA, 
1997b) 
150  
No safety concern d) 
Category B c) 
 
09.236 Methyl undec-9-enoate 
O
O
(E)-isomer shown  
2750 
2101 
5760-50-9 
342 
JECFA specification (JECFA, 
2000d) 
34  
No safety concern b) 
Deleted c) 
JECFA evaluated 
methyl 9-undecanoate 
(CASrn as in Register). 
(Z)- or (E)-isomer not 
specified by CASrn in 
Register. 
09.237 Ethyl undec-10-enoate 
O
O
 
2461 
10634 
692-86-4 
343 
JECFA specification (JECFA, 
1998b) 
1.5  
No safety concern b) 
Deleted c) 
 
09.238 Butyl undec-10-enoate 
O
O
 
2216 
2103 
109-42-2 
344 
JECFA specification (JECFA, 
2001c) 
0.037  
No safety concern b) 
Category B c) 
 
09.265 Ethyl oct-4-enoate 
O
O
 
3344 
10619 
34495-71-1 
338 
JECFA specification (JECFA, 
2003b) 
1.2  
No safety concern b) 
 
JECFA evaluated ethyl 
cis-4-octenoate (CASrn 
as in Register). CASrn 
in Register refers to (Z)-
isomer. Register name to 
be changed to Ethyl oct-
4Z-enoate. 
09.267 Methyl hex-3-enoate 
O
O
(E)-isomer shown
3364 
10801 
2396-78-3 
334 
JECFA specification (JECFA, 
2001c) 
0.56  
No safety concern b) 
 
Z- or E-isomer not 
specified by name and 
CASrn in Register. 
09.268 Methyl oct-4(cis)-enoate 
O
O
 
3367 
10834 
21063-71-8 
337 
JECFA specification (JECFA, 
2003b) 
0.37  
No safety concern b) 
 
 
09.284 Ethyl dec-4-enoate 
O
O
 
3642 
10578 
76649-16-6 
341 
JECFA specification (JECFA, 
2000d) 
1.8  
No safety concern b) 
 
JECFA evaluated ethyl 
trans-4-decenoate 
(CASrn as in Register). 
CASrn refers to (E)-
isomer. Register name to 
be changed to E-Ethyl 
dec-4-enoate. 
09.290 Ethyl octa-4,7-dienoate 
O
O
 
3682 
 
69925-33-3 
339 
JECFA specification (JECFA, 
2000d) 
1.8  
No safety concern b) 
 
JECFA evaluated ethyl 
cis-4,7-octadienoate 
(CASrn as in Register). 
CASrn in Register refers 
to the (Z)-isomer. 
Register name to be 
changed to Ethyl octa-
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
4Z,7-dienoate. 
09.291 Hex-3-enyl hex-3-enoate 
O
O
 
3689 
 
61444-38-0 
336 
JECFA specification (JECFA, 
1998b) 
3.2  
No safety concern b) 
 
JECFA evaluated cis-3-
hexenyl cis-3-hexenoate 
(CASrn as in Register). 
CASrn in Register refers 
to the (Z)/(Z)-isomer. 
Register name to be 
changed to Hex-3Z-enyl 
hex-3Z-enoate. 
09.298 Methyl non-3-enoate 
O
O
(E)-isomer shown  
3710 
 
13481-87-3 
340 
JECFA specification (JECFA, 
2000d) 
1.6  
No safety concern b) 
 
JECFA evaluated 
methyl 3-nonenoate 
(CASrn as in Register). 
(Z)- or (E)-isomer not 
specified by CASrn in 
Register. 
09.421 Citronellyl isobutyrate 
O
O 2313 
296 
97-89-2 
71 
JECFA specification (JECFA, 
2003b) 
11  
No safety concern d) 
Category A c) 
R- or S-enantiomer not 
specified by CASrn in 
Register. 
09.424 Neryl isobutyrate 
O
O
2775 
299 
2345-24-6 
73 
JECFA specification (JECFA, 
2003b) 
1.7  
No safety concern d) 
Category B c) 
 
09.431 Geranyl isobutyrate 
O
O
2513 
306 
2345-26-8 
72 
JECFA specification (JECFA, 
2001c) 
110  
No safety concern d) 
Category B c) 
 
09.453 Geranyl isovalerate O
O  
2518 
448 
109-20-6 
75 
JECFA specification (JECFA, 
2000d) 
41  
No safety concern d) 
Category B c) 
 
09.465 Rhodinyl isovalerate 
O
O
2987 
460 
7778-96-3 
77 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern d) 
Deleted c) 
CASrn in Register refers 
to 3S-enantiomer. 
09.471 Neryl isovalerate 
O
O
2778 
508 
3915-83-1 
76 
JECFA specification (JECFA, 
1997b) 
0.024  
No safety concern d) 
Category B c) 
 
09.515 Geranyl 2-ethylbutyrate 
O
O
3339 
11667 
73019-14-4 
78 
JECFA specification (JECFA, 
2001c) 
0.49  
No safety concern d) 
 
 
09.517 Methyl citronellate O
O
3361 
10781 
2270-60-2 
354 
JECFA specification (JECFA, 
2000d) 
0.13  
No safety concern b) 
 
R- or S-enantiomer not 
specified by CASrn in 
Register. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.524 Ethyl 2-methylpent-3-enoate 
O
O
(Z)-isomer shown  
3456 
10612 
1617-23-8 
350 
JECFA specification (JECFA, 
2001c) 
4.9  
No safety concern b) 
 
JECFA evaluated ethyl 
2-methyl-3-pentenoate 
(CASrn as in Register). 
(Z)- or (E)-isomer nor 
(R) or (S) enantiomer 
not specified by 
Register CASrn. 
09.527 Ethyl 2-methylpent-4-enoate 
O
O 3489 
10613 
53399-81-8 
351 
JECFA specification (JECFA, 
1998b) 
0.024  
No safety concern b) 
 
(R) or (S) enantiomer 
not specified by 
Register CASrn. 
09.540 Ethyl 2-methylpenta-3,4-
dienoate 
O
O 3678 
 
60523-21-9 
353 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern e) 
 
(R) or (S) enantiomer 
not specified by 
Register CASrn. 
09.546 Hexyl-2-methylpent-(3 and 4)-
enoate 
O
O
O
O
(Z)-isomer shown
 
3693 
 
58625-95-9 
352 
JECFA specification (JECFA, 
2001c) 
0.024  
No safety concern b) 
 
JECFA evaluated hexyl 
2-methyl-3&4-
pentenoate (mixture) 
(CASrn as in Register). 
Register CASrn refers to 
the (E)-isomer. (R) or 
(S) enantiomer not 
specified by Register 
CASrn. 
09.571 Hex-3-enyl valerate O
O
(Z)-isomer shown  
3936 
10686 
35852-46-1 
1278 
JECFA specification (JECFA, 
2003b) 
6.1  
No safety concern f) 
 
JECFA evaluated cis-3-
hexenyl valerate (CASrn 
as in Register). Register 
CASrn refers to the (Z)-
isomer.  
09.646 Methyl linolenate 
O
O
 
3411 
714 
301-00-8 
346 
JECFA specification (JECFA, 
2003b) 
ND  
No safety concern b) 
Category A c) 
JECFA evaluated a 
mixture of methyl 
linoleate and methyl 
linolenate (CASrn as in 
Register). Register 
CASrn refers to the 
(Z)/(Z)/(Z)-isomer (i.e. 
methyl linolenate). 
09.655 3-Methylbut-3-enyl acetate 
O
O
 
3991 
 
5205-07-2 
1269 
JECFA specification (JECFA, 
2003b) 
7.3  
No safety concern f) 
 
 
09.927 Rhodinyl butyrate 
O
O
2982 
 
141-15-1 
68 
JECFA specification (JECFA, 
2005b) 
ND  
No safety concern d) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.940 Rhodinyl isobutyrate 
O
O
2983 
 
138-23-8 
74 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern d) 
 
JECFA CASrn 1338-23-
8 not valid. 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (SCF, 1995). 
b) (JECFA, 2000a). 
c) (CoE, 1992). 
d) (JECFA, 1999b). 
e) (JECFA, 2007c). 
f) (JECFA, 2004a). 
 
 
Flav
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
Flavouring Group Evaluation 06, Revision 2 
 
 
42 EFSA Journal 2011;9(3):1844 
 
Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for SafetyE valuation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for 47 of the 48 candidate substances in the 
present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.06Rev2 (EFFA, 
2001c; EFFA, 2002a; EFFA, 2004v; EFFA, 2006d; EFFA, 2007a; Flavour Industry, 2004a). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.125 - 
- 
- 
- 
4 
10 
- 
- 
- 
- 
4 
10 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
4 
10 
4 
10 
- 
- 
- 
- 
02.138 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.152 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.170 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.175 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.176 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.195 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.201 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.222 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
Flavouring Group Evaluation 06, Revision 2 
 
 
44 EFSA Journal 2011;9(3):1844 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.06Rev2 (EFFA, 
2001c; EFFA, 2002a; EFFA, 2004v; EFFA, 2006d; EFFA, 2007a; Flavour Industry, 2004a). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.234 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
- 
- 
5 
25 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
05.061 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.082 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.143 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
- 
- 
- 
- 
2 
10 
4 
20 
3 
15 
2 
10 
05.174 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.203 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.217 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.218 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.220 0,05 
0,16 
- 
- 
0,08 
0,16 
0,04 
0,08 
- 
- 
0,1 
8 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0,05 
0,1 
0,08 
0,16 
0,1 
0,2 
- 
- 
08.074 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.100 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.102 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
09.341 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.368 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.377 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.567 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.569 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.572 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.575 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.612 7 
35 
2 
10 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.638 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.640 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.643 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.672 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.673 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.831 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.838 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.855 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.871 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.872 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.884 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.885 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.897 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.06Rev2 (EFFA, 
2001c; EFFA, 2002a; EFFA, 2004v; EFFA, 2006d; EFFA, 2007a; Flavour Industry, 2004a). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
09.898 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.928 7 
35 
5 
25 
10 
50 
7 
35 
7 
35 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.937 0,02 
0,4 
0,02 
0,4 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
2 
40 
0,4 
8 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
- 
- 
- 
- 
0,02 
0,4 
- 
- 
2 
40 
2 
40 
0,02 
0,4 
0,02 
0,4 
09.938 1 
5 
1 
5 
10 
50 
1 
5 
1 
5 
100 
500 
20 
100 
10 
50 
1 
5 
1 
5 
- 
- 
- 
- 
1 
5 
- 
- 
100 
500 
100 
500 
1 
5 
1 
5 
09.939 0,02 
0,4 
0,2 
0,4 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
2 
40 
0,4 
8 
0,2 
4 
0,02 
0,4 
0,02 
0,4 
- 
- 
- 
- 
0,02 
0,4 
- 
- 
2 
40 
2 
40 
0,02 
0,4 
0,02 
0,4 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for each of the 47 flavouring substances in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2001c; EFFA, 2002a; EFFA, 
2004v; EFFA, 2006d; EFFA, 2007a; Flavour Industry, 2004a). The mTAMDI values are only given for the 
highest reported normal use levels. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
02.125 Undec-10-en-1-ol 3900 Class I 1800 
02.138 Dec-9-en-1-ol 3900 Class I 1800 
02.152 Hept-3-en-1-ol 3900 Class I 1800 
02.170 Lavandulol 3900 Class I 1800 
02.175 2-Methylbut-3-en-1-ol 3900 Class I 1800 
02.176 3-Methylbut-3-en-1-ol 3900 Class I 1800 
02.195 Octa-3,5-dien-1-ol 3900 Class I 1800 
02.201 Pent-4-en-1-ol 3900 Class I 1800 
02.222 3-Pentenol-1 3900 Class I 1800 
02.234 3-Nonen-1-ol 3900 Class I 1800 
05.061 Oct-6-enal 1600 Class I 1800 
05.082 Dodeca-3,6-dienal 1600 Class I 1800 
05.174 Pent-4-enal 1600 Class I 1800 
05.203 9-Octadecenal 1600 Class I 1800 
05.217 5-Decenal 1600 Class I 1800 
05.218 16-Octadecenal 1600 Class I 1800 
05.220 4Z-Dodecenal 36 Class I 1800 
08.074 Dec-3-enoic acid 3200 Class I 1800 
08.100 4-Methylpent-3-enoic acid 3200 Class I 1800 
08.102 Non-3-enoic acid 3200 Class I 1800 
09.341 Citronellyl hexanoate 3900 Class I 1800 
09.368 Ethyl 4-methylpent-3-enoate 3900 Class I 1800 
09.377 Ethyl oct-3-enoate 3900 Class I 1800 
09.567 Hex-3-enyl decanoate 3900 Class I 1800 
09.569 Hex-3-enyl octanoate 3900 Class I 1800 
09.572 Hex-4-enyl acetate 3900 Class I 1800 
09.575 3-Hexenyl heptanoate 3900 Class I 1800 
09.612 Lavandulyl acetate 3900 Class I 1800 
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09.638 Methyl dec-4-enoate 3900 Class I 1800 
09.640 Methyl deca-4,8-dienoate 3900 Class I 1800 
09.643 Methyl geranate 3900 Class I 1800 
09.672 Non-3-enyl acetate 3900 Class I 1800 
09.673 Non-6-enyl acetate 3900 Class I 1800 
09.674 Nona-3,6-dienyl acetate  Class I 1800 
09.831 Ethyl 3,7-dimethyl-2,6-octadienoate 3900 Class I 1800 
09.838 3-Hexenyl methyl carbonate 3900 Class I 1800 
09.855 trans-3-Hexenyl hexanoate 3900 Class I 1800 
09.871 Citronellyl decanoate 3900 Class I 1800 
09.872 Citronellyl dodecanoate 3900 Class I 1800 
09.885 Hex-3-enyl hexadecanoate 3900 Class I 1800 
09.897 3-Methylbut-3-en-1-yl butyrate 3900 Class I 1800 
09.898 3-Methylbut-3-en-1-yl hexanoate 3900 Class I 1800 
09.928 trans-3-Hexenyl acetate 3900 Class I 1800 
09.937 Methyl (3Z)-hexenoate 800 Class I 1800 
09.938 6-Methyl-5-hepten-2-yl acetate 40000 Class I 1800 
09.939 Ethyl (3Z)-hexenoate 800 Class I 1800 
05.143 2,5-Dimethyl-2-vinylhex-4-enal 1600 Class II 540 
09.884 Hex-3-enyl-2-ethylbutyrate 3900 Class II 540 
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ANNEX III: METABOLISM 
III.1. Introduction 
The present FGE consists of 48 straight- and branched-chain unsaturated primary alcohols, aldehydes, 
carboxylic acids and esters. 
 
Groups with 70 related supporting substances has been evaluated by the JECFA (JECFA, 1998a; JECFA, 
1999a; JECFA, 2004b) 
III.2. Absorption, Distribution and Elimination 
Specific information regarding absorption, distribution, metabolism and excretion is not available for any of 
the candidate substances. 
However, in general, short chain (< C8) linear and branched-chain saturated/unsaturated aliphatic esters, 
alcohols, aldehydes and carboxylic acids are absorbed from the gastrointestinal tract (JECFA, 2000a; 
Dawson et al., 1964b; Gaillard & Derache, 1965). Long-chain carboxylic acids, such as linoleic acid and 
oleic acid, are readily absorbed from micelles in the jejunum, re-esterified with glycerol in chylomicrons and 
transported via the lymphatic system (Borgström, 1974). Radiolabeled linoleic and oleic acids have been 
administered by different routes to a variety of mammals and humans, demonstrating that fatty acid uptake 
occurs in all tissues, including the brain, by passive/facilitated diffusion and/or active transport 
(Dhopeshwarkar & Mead, 1973; Harris et al., 1980; Abumrad et al., 1984; Schulthess et al., 2000). Large 
lipid soluble organic molecules are absorbed by passive diffusion across hydrofobic domains in cell 
membranes (Klaassen, 1996). 
A more detailed discussion follows on metabolism of linear saturated/unsaturated primary alcohols, 
aldehydes and carboxylic acids, and branched-chain unsaturated primary alcohols, aldehydes, and carboxylic 
acids.  
A relevant discussion of the general aspects of metabolism for these types of substances may be found in 
FAO/WHO JECFA 42/51 (JECFA, 2000a). 
III.3. Metabolism 
III.3.1. Hydrolysis of Esters in vitro 
Aliphatic esters are hydrolysed to the component alcohols and carboxylic acids as shown in Figure III.1. The 
carboxylesterase or esterase classes of enzymes, the most important of which are the beta-esterases, catalyse 
ester hydrolysis (Heymann, 1980). In mammals, these enzymes occur throughout the body in most tissues 
(Heymann, 1980), but predominate in the hepatocytes (Heymann, 1980). The substrate specificity of beta-
carboxylesterase isoenzymes has been correlated with the structure of the alcohol and carboxylic acid 
components (i.e. R and R’, see Figure III.1) (Heymann, 1980). 
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Figure III.1. Ester hydrolysis. 
 
In vitro hydrolysis studies of various esters have been performed with specific carboxylesterase isoenzymes 
isolated from pig and rat livers (Junge & Heymann, 1979; Arndt & Krisch, 1973). Different isoenzymes 
showed large differences in hydrolysis rates, pending on the chain length of carboxyl and alcohol moiety. 
The authors concluded that it appears reasonable to assume a coorperative and complementary function of 
the different carboxylesterase enzymes in the hydrolysis of the various esters (Junge & Heymann, 1979). 
In vitro hydrolysis data have been reported for structurally related esters of saturated linear and branched-
chain carboxylic acids. Butyl acetate, ethyl butyrate, ethyl heptanoate, ethyl nonanoate and ethyl laurate were 
10 to 37 % hydrolysed in artificial gastric juice (pH 1.2 at 37 °C) in two hours, and 72 to 100 % hydrolysed 
in artificial pancreatic juice (pH 7.5 at 37 °C) in one to two hours (Gangolli & Shilling, 1968). The half-lives 
of ethyl butyrate, ethyl heptanoate and ethyl laurate are in the range from 490 to 770 minutes in artificial 
gastric juice and from approximately 5.7 to 9.8 minutes in artificial pancreatic juice (Longland et al., 1977). 
The half-lives of butyl acetate, isoamyl butyrate, ethyl hexanoate, and ethyl heptanoate were 0.0491 to 0.492 
seconds in rat liver tissue preparations and 0.0108 to 0.550 seconds in rat small intestinal mucosa (Longland 
et al., 1977). A concentration of 15 microlitre citronellyl acetate/l was reported to be completely hydrolysed 
within two hours by simulated intestinal fluid containing pancreatin (Grundschober, 1977). A concentration 
of < 18 microlitre citronellyl phenylacetate/l was reported to be 60 % hydrolysed within two hours 
(Grundschober, 1977). 
Generally hydrolysis appears to be faster in homogenates from rat liver and intestinal mucosa than in 
artificial gastric and pancreatic juices (Longland et al., 1977). 
An in vitro hydrolysis study on carbonate esters of alpha-, beta-naphtol and p-nitrophenol showed that 
carbonate esters are also hydrolysed by liver carboxyl esterase from human, rat and mouse (Huang et al., 
1993). 
In vitro hydrolysis data from studies with esters related to the candidate substances, indicate that the esters 
included in this evaluation can be hydrolysed in the gut to yield the corresponding alcohols and carboxylic 
acids of the esters prior to absorption or in the liver following absorption (Grundschober, 1977; Longland et 
al., 1977; Gangolli & Shilling, 1968; Leegwater & Straten, 1974a). 
III.3.2. Metabolism of Linear Saturated/Unsaturated Primary Alcohols, Aldehydes and Carboxylic acids 
The alcohols formed via ester or acetal hydrolysis are subsequently oxidized to the corresponding aldehydes 
(formed by the oxidation of alcohols to their corresponding aldehydes), which are efficiently oxidized to the 
corresponding saturated/unsaturated carboxylic acids by high capacity enzyme pathways. Isoenzyme 
mixtures of NAD+/NADH-dependent alcohol dehydrogenase (ADH) obtained from human liver microsomes 
have been reported to catalyse oxidation of linear primary aliphatic saturated/unsaturated alcohols 
(Pietruszko et al., 1973). A comparison of the alcohol structure with enzyme binding affinity of ADH 
indicates that increased binding (lower Km) occurs with increasing chain length (i.e. C1 to C6) of the 
substrate and the presence of unsaturation. However, maximum reaction rates of oxidation are essentially 
constant regardless of the alcohol structure suggesting that alcohol-enzyme binding is not the rate limiting 
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step for oxidation; rather, the activity of this enzyme appears to be dependent upon the lipophilic character of 
the alcohol substrate (Klesov et al., 1977). 
Similarly, aldehyde dehydrogenase (ALDH) present predominantly in hepatic cytosol exhibits broad 
specificity for oxidation of aldehydes (Feldman & Weiner, 1972; Eckfeldt & Yonetani, 1982). ALDH is 
more active for higher molecular weight aldehydes (Nakayasu et al., 1978). Xanthine oxidase and aldehyde 
oxidase also catalyse oxidation of a wide range of aldehydes to the corresponding unsaturated carboxylic 
acids (Beedham, 1988). 
At elevated levels of exposure and prior to oxidation to the corresponding carboxylic acid, the aldehyde may 
conjugate with sulphydryl groups such as glutathione to yield thiohemiacetals. Oxidation of low molecular 
weight aldehydes requires glutathione which implies that the substrate for ALDH-mediated oxidation may be 
the thiohemiacetal (Brabec, 1993).  
 
Figure III.2. Metabolism of linear unsaturated carboxylic acid, 
 
The resulting linear saturated/unsaturated carboxylic acids participate in normal fatty acid metabolism 
(Figure III.2). In this pathway, the carboxylic acid is condensed with coenzyme A (CoA) followed by 
catalytic dehydrogenation mediated by acyl CoA dehydrogenase (Voet & Voet, 1990). The resulting trans-
2,3-unsaturated ester (trans-delta2-enoyl CoA) is converted to the 3-ketothioester, which undergoes beta-
cleavage to yield an acetyl CoA fragment and a new thioester reduced by two carbons. 
Cleavage of acetyl CoA units will continue along the carbon chain until the position of unsaturation is 
reached. If the unsaturation begins at an odd-numbered carbon, acetyl CoA fragmentation will eventually 
yield a delta3-enoyl CoA, which cannot enter the fatty acid cycle until it is isomerised to the trans-delta2-
enoyl CoA by enoyl CoA isomerase. If unsaturation begins at an even-numbered carbon, acetyl CoA 
fragmentation yields a delta2-enoyl CoA product, which is a substrate for further fatty acid oxidation. If the 
stereochemistry of the double bond is cis, it is isomerised to the trans double bond by the action of 3-
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hydroxyacyl CoA epimerase prior to entering the fatty acid oxidation pathway. Even-numbered carbon acids 
continue to be cleaved to acetyl CoA while odd-numbered carbon acids yield acetyl CoA and propionyl 
CoA. Acetyl CoA enters the citric acid cycle directly while propionyl CoA is transformed into succinyl CoA 
that then enters the citric acid cycle. 
Alternate minor metabolic pathways have been characterised for linear long-chain fatty acids and short-chain 
carboxylic acids containing unsaturation. While linoleic and oleic acids participate in beta-oxidation and 
normal fatty acid metabolism in most tissues (Masoro, 1977), they may undergo omega-oxidation in the liver 
and alpha-oxidation in the brain (Wakil & Barnes, 1971; Gibson et al., 1982).  
Unsaturated short-chain carboxylic acids may be metabolised via saturation to yield a substrate that may 
participate in the fatty acid pathway. For example, the mechanism for oxidative metabolism of 4-pentenoic 
acid has been studied in rat heart mitochondria. In vitro 4-pentenoic acid is converted to the CoA thioester, 
which is dehydrogenated to yield the trans-2,4-pentadienoyl CoA (Figure III.3). Two enzyme-catalysed 
processes then compete for this conjugated thioester. In the first pathway, NADPH-dependent enzyme-
catalysed reduction of the delta4-alkene leads to trans-2-pentenoic acid. The second pathway involves beta-
oxidation to yield 3-keto-4-pentenoyl CoA. In vitro hydrogenation predominates to yield trans-2-pentenoic 
acid, which then participates in normal fatty acid oxidation (Schulz, 1983). 
 
 
Figure III.3. Metabolism of 4-pentenoic acid. 
III.3.3. Metabolism of Branched-chain Unsaturated Primary Alcohols, Aldehydes and Carboxylic Acids 
Generally, branched-chain aliphatic alcohols are oxidized to the corresponding aldehydes, which in turn are 
oxidized to the corresponding carboxylic acids (Bosron & Li, 1980; Levi & Hodgson, 1989). Branched-chain 
aliphatic alcohols and aldehydes have been reported to be substrates for ADH (Hedlund & Kiessling, 1969a; 
Albro, 1975) and ALDH (Hedlund & Kiessling, 1969a), respectively. As carbon chain length increases, the 
substrate-enzyme binding affinity with ADH (Pietruszko et al., 1973) and the rates of ALDH-mediated 
oxidation also increase (Nakayasu et al., 1978). 
Similar to their saturated analogs, unsaturated branched-chain aliphatic alcohols and aldehydes are converted 
by the pathways cited above to the corresponding carboxylic acids, which participate in the normal fatty acid 
metabolism (Voet & Voet, 1990). 
Alternatively, they may undergo a combination of omega, omega-1, and beta-oxidation to yield polar 
metabolites, which are excreted as such or as glucuronic acid conjugates in the urine (Diliberto et al., 1990). 
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The principal metabolic pathways utilized for metabolisation of these branched-chain substances are 
determined primarily by four structural characteristics: carbon chain length, position of alkyl substituents, 
number of alkyl substituents and size of alkyl substituents. 
Short-chain (< C6) branched aliphatic carboxylic acids undergo beta-oxidation, preferentially in the longer 
chain. Beta-cleavage of the branched aliphatic carboxylic acids yields linear carboxylic acid fragments, 
which are sources of carbon in the fatty acid metabolism pathway or tricarboxylic acid cycle (Voet & Voet, 
1990). For example, a single oral dose of 4.5, 45, or 450 mg/kg [1-14C]-isobutyric acid given to male Charles 
River CD rats by gavage was rapidly eliminated in the breath as expired 14CO2. Within 24 hours of dosing, 
77, 78, or 83 % of the 4.5, 45, or 450 mg/kg dose, respectively, was eliminated as CO2 (DiVincenzo & 
Hamilton, 1979). 
Methyl methacrylate given to rats by gavage was also eliminated mainly as CO2 (Bratt & Hathway, 1977). 
The hydrolysis of one candidate substance hex-3-enyl-2-ethylburtyrate [FL-no: 09.884] generates 2-
ethylbutyric acid [FL-no: 08.045], which has some teratogenic potential (see Section 8.3). Although the 2-
ethyl-branched acid is resistant to beta-oxidation, it can be further conjugated with glucuronic acid or 
undergo omega-oxidation. However, the candidate substance [FL-no: 09.884] cannot be anticipated to be 
metabolised to an innocuous product. 
Terminal double bonds appear in eleven candidate substances [FL-no: 02.125, 02.138, 02.170, 02.175, 
02.176, 02.201, 05.143, 05.174, 09.612, 09.897 and 09.898]. Of these, six are unsaturated alcohols [FL-no: 
02.125, 02.138, 02.170, 02.175, 02.176 and 02.201] two are unsaturated aldehydes [FL-no: 05.143 and 
05.174], and three are unsaturated esters [FL-no: 09.612, 09.897, and 09.898]. These double bonds may be 
oxidized to the corresponding epoxides. Epoxides are highly reactive molecules, due to the large strain 
associated with the three membered ring structure, and they react easily with nucleophilic sites of cellular 
macromolecules. For this reason, several aliphatic alkene-derived epoxides have been demonstrated to be 
carcinogenic (e.g. ethylene, isoprene, butadiene, glycidol) (Melnick, 2002). Alternatively, epoxides can be 
conjugated with glutathione (GSH) by glutathione S-tansferases (GSTs) or hydrolysed to diols by epoxide 
hydrolases (EHs). The latter two reactions can be considered to be detoxifications.  
It has been demonstrated that terminal double bonds may be oxidized at the double bond to give the 
corresponding epoxide or, alternatively, at the allylic carbon to give the allylic alcohol, as was demonstrated 
with 1-hexene with rat and human P450s (Chiappe et al., 1998). The ratio of epoxidation over allylic 
oxidation, as measured with different P450 isoforms (CYP) is ≥1, indicating that epoxide formation is 
generally favoured (Chiappe et al., 1998). Theoretically these pathways could occur with the candidate 
substances [FL-no: 02.125, 02.138, 02.175, 02.201, 06.143 and 05.174].  
In the same paper (Chiappe et al., 1998) it was demonstrated that the biotransformation of 2-methyl-1-
hexene proceeds exclusively via the epoxide, which was further hydrolysed by EH to the diol. This pathway 
might apply to the alcohols [FL-no: 02.170 and 02.176] and to the alcohol moiety of [FL-no: 09.612, 09.897 
and 09.898] 
However, the risk associated with the epoxidation of the terminal double bond of these candidate substances 
is expected to be low for several reasons:  
1) epoxides can be metabolised by conjugation with glutathione or by epoxide-hydrolase mediated 
hydrolysis. 
2) The terminal double bonds are all present in molecules that have alcohol- or aldehyde functions 
at the end distal from the double bond, or that are alcohol moieties of esters. The alcohol- and 
aldehyde functions can be expected to be readily attacked by oxidation processes, ultimately 
yielding unsaturated carboxylic acids, and also hydrolysis of the esters would yield the 
unsaturated alcohols, which will be oxidised to carboxylic acids. Biochemical attack of these 
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carboxylic acids via e.g. beta-oxidation or conjugation with glucuronic acid is expected to be 
much more efficient and rapid than microsomal oxidation. 
Rats metabolised geraniol and citral (unsaturated branched-chain alcohol and aldehyde, respectively) largely 
via omega-oxidation to yield a mixture of diacids and hydroxy acids (Diliberto et al., 1990; Chadha & 
Madyastha, 1984). Geraniol related terpenoid alcohols (citronellol and nerol), and the aldehydes (geranial, 
citronellal and neral) exhibit similar pathways of metabolic metabolisation in animals (Figure III.4). 
 
 
Figure III.4. Metabolism of Geraniol in rats. 
 
Male rats were given repeated oral doses of 800 mg [1-3H]-geraniol/kg bw by gavage daily for 20 days. Five 
urinary metabolites were identified via two primary pathways. In one pathway, the alcohol is oxidized to 
yield geranic acid (3,7-dimethyl-2,6-octadieneoic acid), which is subsequently hydrated to yield 3,7-
dimethyl-3-hydroxy-6-octenoic acid. In a second pathway, the alcohol undergoes omega-oxidation mediated 
by liver cytochrome P-450 (Chadha & Madyastha, 1982) to yield 8-hydroxygeraniol. Selective oxidation at 
C-8 yields 8-carboxygeraniol, which undergoes further oxidation to the principal urinary metabolite 2,6-
dimethyl-2,6-octadienedioic acid (Chadha & Madyastha, 1984). 
Mono methyl substituted fatty acids are extensively metabolised to CO2 via beta-oxidative cleavage in the 
fatty acid pathway. If more than one methyl group is substituted in the lower as well as higher molecular 
weight acids or ethyl or propyl substituents are present, beta-oxidation is inhibited. In those cases 
metabolism involves direct conjugation of the acid with glucuronic acid, or omega-oxidation followed by 
conjugation (Williams, 1959a; Deuel, 1957). 
III.4. Summary and Conclusions 
In summary, it is anticipated that the esters in the group of 48 candidate substances will undergo hydrolysis 
in the gastrointestinal tract, blood and liver to yield their corresponding aliphatic alcohols, aldehydes and 
carboxylic acids. Esters, aliphatic alcohols, aldehydes and carboxylic acids are expected to be absorbed from 
the gastrointestinal tract. Alcohols would be oxidized to their corresponding aldehydes and carboxylic acids, 
and aldehydes would be oxidized to their corresponding carboxylic acids. The resulting aliphatic carboxylic 
acids undergoes complete metabolism to CO2 in the tricarboxylic acid cyclic and fatty acid pathway. 
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The following substances [FL-no: 02.170, 02.176, 09.612, 09.884, 09.341, 09.643, 09.871, 09.872, 09.831, 
09.897 and 09.898] are not completely oxidized to CO2 due to substitution in the beta-position or sterich 
hindrance. These substances, the esters after hydrolysis, are expected to undergo oxidation reactions and to 
be excreted as such  or after conjugation with glucuronic acid. Hex-3-enyl-2-ethylburtyrate [FL-no: 09.884], 
is hydrolysed to 2-ethylbutyric acid and hex-3-enol, which can be further conjugated with glucuronic acid or 
undergo omega-oxidation. However, the candidate substance [FL-no: 09.884] cannot be anticipated to be 
metabolised to an innocuous product. 
The risk associated with possible epoxidation of the candidate substances with terminal double bond is 
expected to be low for two reasons. Epoxides can be metabolised by conjugation with glutathione or by 
epoxide-hydrolase mediated hydrolysis. The terminal double bonds in this group of flavourings are all 
present in molecules that have alcohol- or aldehyde functions at the end distal from the double bond, and the 
alcohol and aldehyde functions are expected to be metabolised to carboxylic acids prior to epoxidation of the 
double bond. 
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ANNEX IV: TOXICITY 
Acute toxicity data are available for four candidate substances of the present flavouring group of 48 substances from chemical groups 1 and 4, and for 42 
supporting and structurally related substances evaluated by the JECFA at the 49th, 51st and 61st meetings (JECFA, 1998a; JECFA, 1999a; JECFA, 2004b). The 
supporting substances are listed in brackets. 
 
Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species Sex Route LD50 (mg/kg bw) Reference Comments 
(4-Pentenoic acid [08.048]) Mouse NR Gavage 610 (Jenner et al., 1964)  
Rat M/F Gavage 470 (Jenner et al., 1964)  
Pent-4-enal [05.174] Rat F Gavage 620 (Smyth et al., 1962)  
(cis-3-Hexen-1-ol [02.056]) Mouse M Gavage 7000 (Gaunt et al., 1969)  
Mouse F Gavage 7200 (Gaunt et al., 1969)  
Rat M/F Oral 4700 (Moreno, 1973b)  
Rat M Gavage 10100 (Gaunt et al., 1969)  
Rat F Gavage 7300 (Gaunt et al., 1969)  
(cis-3-Hexenal [05.075]) Rat M/F Gavage 1560 (Palanker & Lewis, 1979)  
((Z,Z)-3,6-Nonadien-1-ol1 [02.189]) Rat M/F Oral 2000 (Koike, 1996)  
(cis-6-Nonenal [05.059]) Mouse NR Oral 5000 (Moreno, 1978b)  
(9-Decenal1 [05.139]) Mouse M/F Gavage 9500 (Johnson, 1980) LD50 > 5 ml/kg. 
(10-Undecenal [05.035]) Rat NR Oral 5000 (Hart & Wong, 1971)  
(10-Undecenoic acid [08.039]) Mouse NR Gavage  8150 (Newell et al., 1949)  
Mouse NR Oral 2300-6600 (Tislow et al., 1950)  
Rat NR Oral 2500 (Tislow et al., 1950)  
(Oleic acid [08.013]) Rat NR Oral 5000 (Moreno, 1977b)  
Rat NR Oral 19000 (Briggs et al., 1976) LD50 was > 21.5 ml for ocadecanoic 
acid (75 % oleic acid) and 
octadecadienoic acid (53 % linoleic 
acid, 23 % oleic acid). 
(cis-3-Hexenyl propionate1 [09.564]) Rat NR Oral 5000 (Moreno, 1976f)  
(cis-3-Hexenyl valerate1) Rat NR Oral 5000 (Moreno, 1978d) 1/10 rats died after a dose of 5000 
mg/kg. 
(Ethyl cis-4,7-octadienoate [09.290]) Rat M/F Gavage 10000 (Mondino, 1979)  
(Methyl 9-undecenoate [09.236]) Rat M Oral 3000 (Moreno, 1977b)  
(Ethyl 10-undecenoate [09.237]) Rat NR Oral 5000 (Moreno, 1977b)  
(Butyl 10-undecenoate [09.238]) Rat NR Oral 5000 (Moreno, 1977b)  
(Ethyl oleate [09.192]) Rat NR Oral 5000 (Bailey, 1976d) 1/10 rats died after a dose of 5000 
mg/kg. 
Methyl-3-but-3-en-1-ol [02.176] Rat NR Oral 5440 (BASF, 1968)  
(2,6-Dimethyl-5-heptenal [05.074]) Rat NR Oral 5000 (Levenstein, 1974b)  
Rat M/F Gavage 4550 (Mayyasi et al., 1981) LD50 > 5 ml/kg. 
Lavandulol [02.170] Mouse NR Oral 5000 (Moreno et al., 1982) 4/10 mice died after a dose of 5000 
mg/kg. 
(3-Hexenyl isobutyrate1 [09.563]) Rat  M/F Gavage 25000 (Moran et al., 1980)  
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Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species Sex Route LD50 (mg/kg bw) Reference Comments 
Mouse M/F Gavage  25000 (Moran et al., 1980)  
(Hexyl 2-methyl-3&4-pentenoate [09.546]) Rat M/F Gavage 5000 (Elleman, 1979)  
(Ethyl 2-methyl-3,4-pentadienoate [09.540]) Mouse M Gavage 1316 (Babish, 1978c)  
Mouse F Gavage 892 (Babish, 1978c)  
Mouse M/F Gavage 770 (Moran et al., 1980)  
(Citronellyl formate [09.078]) Rat M/F Gavage 8400 (Calandra, 1971)  
(Geranyl formate [09.076]) Rat M/F Gavage 5460 (Weir & Wong, 1971a) LD50 > 6 ml/kg. 1/5 rats died after 6 
ml/kg. 
(Neryl formate [09.212]) Rat NR Oral  5000 (Moreno, 1975f)  
(Rhodinyl formate [09.079]) Rat NR Oral  5000 (Moreno, 1974a) 1/10 rats died after a dose of 5000 
mg/kg. 
(Citronellyl acetate [09.012]) Rat M/F Gavage 6800 (Calandra, 1971)  
(Geranyl acetate [09.011]) Rat M/F Gavage 6330 (Jenner et al., 1964)  
(Neryl acetate [09.213]) Rat M/F Gavage 4550 (Levenstein & Wolven, 1972a) LD50 > 5 ml/kg. 
(Rhodinyl acetate [09.033]) Rat M/F Gavage 5000 (Levenstein, 1973a) LD50 > 5 ml/kg. 
(Citronellyl propionate [09.129]) Rat NR Oral 5000 (Moreno, 1973a) 3/10 rats died after a dose of 5000 
mg/kg. 
(Geranyl propionate [09.128]) Rat NR Oral 5000 (Russell, 1973a)  
(Neryl propionate [09.169]) Rat NR Oral 5000 (Moreno, 1975f)  
(Rhodinyl propionate [09.141]) Rat NR Oral 5000 (Moreno, 1976h)  
(Citronellyl butyrate [09.049]) Rat NR Oral 5000 (Moreno, 1972a) 3/10 rats died after a dose of 5000 
mg/kg. 
(Geranyl butyrate [09.048]) Rat M/F Gavage 10660 (Jenner et al., 1964)  
(Rhodinyl butyrate) Rat NR Oral 5000 (Moreno, 1975f)  
(Geranyl hexanoate [09.067]) Rat NR Oral 5000 (Moreno, 1975f)  
(Citronellyl isobutyrate [09.421]) Rat NR Oral 5000 (Denine & Palanker, 1973a)  
(Geranyl isobutyrate [09.431]) Rat NR Oral 5000 (Shelanski & Moldovan, 1973a)  
(Neryl isobutyrate [09.424]) Rat M Oral 5000 (Moreno, 1980d)  
(Rhodinyl isobutyrate)  Rat NR Oral 5000 (Moreno, 1975f)  
(Geranyl isovalerate [09.453]) Rat NR Oral 5000 (Levenstein, 1975a)  
(Geranyl 2-ethylbutanoate [09.515]) Mouse NR Oral 8000 (Pellmont et al., 1968)  
Undec-10-en-1-ol [02.125] Rat M/F Oral 5000 (Levenstein & Wolven, 1972c) LD50 > 5 ml/kg. 
NR: Not Reported 
1 A substance evaluated at the 61st JECFA meeting structurally related to candidate substances in FGE.06Rev1.
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Subacute / subchronic / chronic /carcinogenicity toxicity data are available for 12 supporting substances of the present flavouring group. They were evaluated 
at the 49th and 51st JECFA meetings (JECFA, 1998a; JECFA, 1999a). No repeated dose studies are available on the candidate substances. The supporting 
substances are listed in brackets. 
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL (mg/kg bw/day) Reference Comments 
(cis-3-Hexen-1-ol [02.056]) Rat; M, F 
30 
Drinking water 0, 310, 1250, 5000 
ppm equal to M: 0, 
30, 127, 410 mg/kg 
bw/day, F: 0, 42, 
168, 721 mg/kg 
bw/day 
98 days 127-168 (Gaunt et al., 1969) NOAEL corresponds to 1250 mg/kg feed. 
(10-Undecenoic acid [08.039]) Rat; M, F 
NR 
Gavage 0, 100, 200, and 400 
mg/kg bw/day 
6 months 400 (Tislow et al., 1950) Total number of animals studied was 152. 
Endpoints included body weight and changes in 
autopsy (only poorly reported abstract 
available). 
Rat; M 
7 
Diet 0, 5000, 10000 and 
25000 mg/kg feed 
equivalent to 0, 500, 
1000 and 2500 mg/kg 
bw/day 
8 weeks 25003  (Newell et al., 1949) Reported only data on body weight. Study 
ongoing at the reporting time. There was a 
reduction in body weight gain at both 
concentration. Doses are considered very high. 
(Oleic acid [08.013]) Rabbit; M, F 
20 
Diet 0, 150000 mg/kg 
feed equivalent to 
4500 mg/kg bw/day 
36 weeks 45003 (Borgman & 
Wardlaw, 1975) 
Groups: (1) olive oil and (2) semipurified oleic 
acid. Treatment included periods with diet 
supplemented with cholesterol. Serum 
cholesterol was the main endpoint. Rabbits fed 
oleic acid began to deteriorate by week 17th. 
Animals showed severe to slight hepatic fatty 
acid degeneration 
Mouse; NR 
36 and 55 
Diet 0, 1500 mg/kg feed 
equivalent to 0, 225 
mg/kg bw/day 
24 months 2253 (El-Khatib & Cora, 
1981) 
Groups were given (1) normal diet, or (2) 
normal diet + corn oil (10 %) + oleic acid 
(0.15%). Main endpoint was lipid content in the 
liver and pituitary gland. There was an increase. 
In 3 of 36 surviving mice given diet with corn 
oil + oleic acid adenocarcinoma of the colon was 
reported. 
Rabbit; M, F 
38-42 
Diet 0, 150000 mg/kg 
feed equivalent to 0, 
4500 mg/kg bw/day 
16 weeks 45003 (Lee et al., 1986) Treated animals were given a diet with 40 % 
casein and 15 % oleic acid. Examined for 
gallbladder content. The treated animals showed 
gallstones. 
(Oleic acid/linoleic acid mixture [08.013] / [08.041]) 
 
Mouse; M, F 
329-623 
Oral (given on 
a separate dish) 
0, 0 and ~ 64-100 
mg/kg bw/day 
≈ 24 months 
(long term, 
exact duration 
not reported) 
 64-100 (Szepsenwol & 
Boschetti, 1975) 
A NOAEL was not determined. Groups: (1) 
untreated (2) refined corn oil, (3) refined corn 
oil with 15 mg/g oleic acid/linoleic acid mixture. 
Mice given treatment (3) had a higher incidence 
of stomach tumours as compared to the other 
two groups. 
Mouse; NR 
195-328 
Oral (given on 
a separate dish) 
0, 0, 0, and ~ 85-100 
mg/kg bw/day 
≈ 24 months 
(long term, 
exact duration 
 85-100 (Szepsenwol, 1978) A NOAEL was not determined. Groups: (1) 
untreated, (2) refined corn oil, (3) crude corn oil, 
and (4) refined corn oil + oleic acid/linoleic acid 
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Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL (mg/kg bw/day) Reference Comments 
not reported) mixture. The mixture oleic acid/linoleic acid 
was carcinogenic, with an increased incidence of 
forestomach papilloma, squamous cell 
carcinoma and pyloric tumours. 
(Hexanoic acid1 [08.009]) Rat; M, F 
10 
Diet 100000 mg/kg feed 
equivalent to 5000 
mg/kg bw/day 
5 months 50003 (Mori, 1953) Endpoint was gastric lesions. No attempt was 
made to estimate the amount ingested by rats 
due to the volatility of fatty acid, which raises 
concerns on the validity of the results. 
(2,6-Dimethyl-5-heptenal [05.074]) Rat; M, F 
30 
Diet 0, 9, 37, and 150 
mg/kg bw/day 
3 months 37 (Gaunt et al., 1983)  
(2-Ethylbutyric acid1 [08.045]) Rat; M, F 
6 
Diet 6000 mg/kg feed 
equivalent to 300 
mg/kg bw/day 
3 months 3003 (Amoore et al., 
1978) 
 
(Citronellyl acetate and geranyl acetate [09.012] and 
[09.011]) 
Mouse; M, F 
20 
Gavage 0, 125, 500, 1000, 
and 2000 mg/kg 
bw/day 
13 weeks 1000 (NTP, 1987a) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate.  
Rat; M, F 
20 
Gavage 0, 250, 500, 1000, 
2000, and 4000 
mg/kg bw/day 
13 weeks 2000 (NTP, 1987a) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate. 
Mouse; M, F 
100 
Gavage 0, 500, and 1000 
mg/kg bw/day 
2 years  500 (NTP, 1987a) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate. Survival 
among males was 62, 64 and 0 %, respectively. 
Survival among females was 50, 30, and 0 %, 
respectivel. The mixture was not considered to 
be carcinogenic. 
(Citronellyl acetate and geranyl acetate [09.012] and 
[09.011], continued)  
Rat; M, F 
100 
Gavage 0, 1000, and 2000 
mg/kg bw/day 
2 years  1000 (NTP, 1987a) The test material was composed of 71 % geranyl 
acetate and 29 % citronellyl acetate. Survival 
among males was 68, 58 and 36%. Survival 
among females was 70, 56 and 66%, 
respectively. The mixture was not considered 
carcinogenic. 
(Geranyl acetate [09.011]) Rat; M, F 
20 
Diet 0, 1000, 2500, and 
10000 mg/kg feed 
equivalent to 0, 50, 
125, 500 mg/kg 
bw/day 
17 weeks 5003 (Hagan et al., 1967)  
(Geraniol2 [02.012]) Rat; M, F 
10 
Diet 0, 10000 mg/kg feed 
equivalent to 500 
mg/kg bw/day 
16 weeks 5003 (Hagan et al., 1967)  
Rat; M, F 
10 
Diet 0, 1000 mg/kg feed 
equivalent to 50 
mg/kg bw/day 
27 – 28 weeks 503 (Hagan et al., 1967)  
(Citronellol2 [02.011]) Rat; M, F 
30 
Diet Incompletely 
reported 
12 weeks 50 (Oser, 1967) The test material was a mixture consisting of 
equal amounts of citronellol and linalool. The 
publication was not provided, only a FAO report 
referring to it. There was a slightly retarded 
growth of males, without effect on food 
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Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL (mg/kg bw/day) Reference Comments 
utilization. No other endpoints are mentioned. 
(Citronellyl isobutyrate [09.421]) Rat; M, F 
28 
Diet 0, 14.7 mg/kg 
bw/day 
3 months 14.7 (Damske et al., 
1980a) 
 
NR = Not Reported. 
NA = Not Applicable.  
1A substance evaluated at the 49th JECFA meeting and structurally related to candidate substances in FGE.06. 
2 A substance evaluated at the 61st JECFA meeting structurally related to candidate substances in FGE.06. 
3 Conversion table for test chemical treatment dosed used in PAFA (FDA, 1993). 
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No developmental and reproductive toxicity studies are available for any candidate substance in the present flavouring group. One study was available for one 
supporting substance and for one hydrolysis product.  
TABLE IV.3: DEVELOPMENTAL / REPRODUCTIVE TOXICITY STUDIES 
Table IV.3: Developmental / Reproductive Toxicity Studies 
Chemical name Study type 
Duration 
Species/sex  
No/group 
Route Dose levels NOAEL 
mg/kg/day 
Including information on 
possible maternal toxicity 
Reference Comments 
(10-Undecenoic acid [08.039]) One generation study 
9 months  
Rat; M, F 
NR 
Gavage  
 
NR NR (Tislow et al., 1950) Only poorly reported 
abstract available. 
(2-Ethylbutyric acid [08.045]) Developmental toxicity; dose 
administered gestation days 6-15 
Rat; F 
9-18 
gavage 0, 150, 200 mg/kg bw 200 (Narotsky et al., 1994)  
Developmental toxicity; dose 
administered gestation day 8 
Mouse; F 
15/group 
Subcutaneo
us injection 
0, 600 mg/kg bw < 600 (Nau & Löscher, 1986) 1 
NR = Not Reported. 
1) In the present study valproic acid as well as a number of related substances was examined with respect to their teratogenic potential.Valproic acid was highly teratogenic at 600 mg/kg/day. The study showed that the teratogenic potential 
increased with the number of carbon-atoms in the 2-position. 
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In vitro mutagenicity/genotoxicity data are available for one candidate substances of the present flavouring group evaluation from chemical group 4 and for 
six supporting substances evaluated at the 49th and 51st JECFA meetings (JECFA, 1998a; JECFA, 1999a). Supporting substances are listed in brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no] Test system Test Object Concentration Result Reference Comments 
 
(9-Decenal1 [05.139]) Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, 
TA1538 
0.001-1 nl/plate (0.001-1 
μg/plate)  
Negative2 (Richold & Jones, 
1980) 
In the absence of metabolic activation, the 
highest concentrations were cytotoxic. The study 
is considered valid. 
(Oleic acid [08.013]) Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, 
TA1538, E. coli 
WP2uvrA 
1 - 5000 μg/plate Negative2 (Shimizu et al., 1985) Modified Ames, preincubation assay. The study 
is considered valid. 
Ames assay S. typh. TA98, TA100, 
TA1535, TA1537 
1 - 0, 333 μg/plate Negative2 (Mortelmans et al., 
1986) 
Modified Ames, preincubation assay. 
Concentrations were selected based on a 
preliminary experiment. The study is considered 
valid. 
Rec assay B. subtilis 100 - 1000 μg/plate Negative2 (Osawa & Namiki, 
1982) 
The validity of this study is unclear. 
SCE test CH V79 2.5 - 10 μg/ml  Negative  (Kinsella, 1982) Not cytotoxic. The assay was only performed 
without metabolic activation. Doses were 
selected based on a preliminary assay. The study 
is considered valid. 
Chrom. abs. CH V79 2.5 - 10 μg/ml  Positive (Kinsella, 1982) There was an increase in numerical 
abnormalities, but not in breaks, not 
concentration dependent. No cytotoxicity was 
observed. The assay was only performed without 
metabolic activation. Doses were selected based 
on preliminary assay. The study is considered 
valid. 
6-TG resistance CH V79 1.0 μg/ml  Negative  (Kinsella, 1982) Not cytotoxic. Only one concentration level. The 
assay was only performed without metabolic 
activation. The validity of the study cannot be 
evaluated. 
(Methyl linoleate & Methyl linolenate (mixture) 
[09.646]) 
Ames (His+ reversion) 
assay 
S. typh. TA100, TA98, 
TA102, TA97, TA1537 
125 - 1000 μg/plate Negative2 (MacGregor et al., 
1985) 
Tests were conducted with methyl linoleate and 
methyl linolenate separately. Both were 
negative. Doses were selected based on 
prelimary assay. The study is considered valid. 
Methyl-3-but-3-en-1-ol [02.176] Ames assay S. typh. TA98, TA100, 
TA1535, TA1537 
20 - 5000 μg/plate Negative2, 5  (BASF, 1989c) The complete report for this study was not 
provided. The validity of this study cannot be 
evaluated. 
(2,6-Dimethyl-5-heptenal [05.074]) Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, 
TA1538 
Up to 3600 μg/plate Negative2 (Wild et al., 1983) Five concentrations tested. The study is 
considered valid. 
Ames assay S. typh. TA98, TA100, 
TA1535, TA1537, 
Up to 50000 μg/plate Negative2 (Heck et al., 1989) No information concerning a possible cytotoxic 
effect nor on the number of concentrations 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no] Test system Test Object Concentration Result Reference Comments 
 
TA1538 tested. The test guidelines do not require more 
than 5 mg/plate. The validity of this poorly 
reported study cannot be evaluated. 
UDS test Rat hepatocytes Up to 1000 μg/ml Negative2 (Heck et al., 1989) No information concerning the number of 
concentrations tested. The validity of this poorly 
reported study cannot be evaluated. 
(Geranyl formate [09.076]) Rec assay B. subtilis 18 μg/disk  Negative (Oda et al., 1979) From english abstract. Only one dose level is 
mentioned in a table. The validity of the study is 
unclear. 
(Geranyl acetate [09.011]) Ames assay S. typh., TA98, TA100, 
TA1535  
Up to 2000 μg/plate  Negative (Heck et al., 1989) No information concerning a possible cytotoxic 
effect nor on the number of concentrations 
tested. The validity of this poorly reported study 
cannot be evaluated.  
Ames assay S. typh., TA98, TA100, 
TA1535, TA1537 
1 - 3333 μg/plate  Negative (Mortelmans et al., 
1986) 
Modified Ames, preincubation assay. Doses 
were selected based on preliminary assay. The 
study is considered valid. 
Rec assay B. subtilis 17 μg/disk  Negative  (Oda et al., 1979) From english abstract. Only one dose level is 
mentioned in a table. The validity of this study is 
unclear. 
Rec assay B. subtilis Up to 20 μl/disk  Negative  (Yoo, 1986) From english abstract. No information 
concerning the number of doses tested. The 
validity of this study cannot be evaluated. 
Gene mutation Mouse; L5178Y TK+/-  Up to 100 μg/ml 
Up to 78 μg/ml 
Negative3;  
Positive4 (weak) 
(Heck et al., 1989) The validity of this poorly reported study cannot 
be evaluated. 
Gene mutation Mouse; L5178Y TK+/-  18.3 μg/ml Negative3;  
Positive4 
(Tennant et al., 1987) Detailed information on this study was not 
provided. The article includes a table presenting 
the results of different genotoxicity and 
carcinogenicity tests performed with several 
compounds.  
SCE test CHO cells 45 - 80 μg/ml;  
50 - 299 μg/ml 
Positive (weak)3;  
Positive (weak) or negative 4  
(Galloway et al., 
1987a) 
Positive results, without metabolic activation, 
were observed at cytotoxic concentrations. 
Doses were selected based on preliminary assay. 
The study is considered valid. 
Chromosomal 
aberrations 
CHO cells 60 - 100 μg/ml;  
50 - 150 μg/ml 
Negative3;  
 
(Galloway et al., 
1987a) 
Doses were selected based on preliminary assay. 
The study is considered valid. 
UDS test Hepatocytes of F344 
male rats 
NR Negative (Mirsalis et al., 1983) Only an abstract is available. The validity of this 
study cannot be evaluated. 
Inhibition of DNA 
synthesis 
CHO cells 113 μmole Negative (Meigs et al., 1995) Only one concentration level is mentioned. The 
validity of this study is unclear. 
UDS test Hepatocytes of F344 
male rats 
Up to 100 nl/ml Negative (Heck et al., 1989) No information concerning the number of 
concentrations tested. The validity of this poorly 
reported study cannot be evaluated. 
Gene mutation Human lymphoblast 
TK6  
Up to 320 μg/ml;  
Up to 500 μg/ml 
Negative3;  
 
(Caspary et al., 1988) Compound precipitation was the limiting factor 
for the maximum concentration. The study is 
considered valid. 
NR = Not Reported. 
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1 A substance evaluated at the 61st JECFA meeting structurally related to candidate substances in FGE.06.  
2With and without metabolic activation.  
3Without rat liver S-9 activation.  
4With rat liver S-9 activation. 
5 Methyl-3-but-3-en-1-ol [FL-no: 02.176] (purity not reported) was tested in a bacterial reversion assay (Ames test) with Salmonella typhimurium strain TA1535, TA100, TA1537 and TA98 with and without exogenous metabolic activation (origin 
not reported), following the standard plate test and pre-incubation test. It is not reported whether a dose range-finding experiment was performed. The main experiments were conducted at a not reported number of doses from 20 to 5000 
microgram/plate. It is not reported whether the doses were tested in duplicate or triplicate. It is not reported the identity of the solvent. 
Result: negative. Eventual bacteriotoxicity or precipitation is not reported.  
Remarks: the available report mentions that the study was performed in accordance with the OECD Guideline 471 “Genetic Toxicology: Salmonella thyphimurium Reverse Mutation Assay”. The available report does not contain sufficient details 
nor is it published in a peer-reviewed journal. The validity of this study cannot be evaluated. 
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In vivo mutagenicity/genotoxicity data are available for two supporting substances of the present flavouring group. They were evaluated at the 49th JECFA 
meetings (JECFA, 1998a). The supporting substances are listed in brackets.  
Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no] Test system Test Object Rout
e 
Dose Result Reference Comments 
(2,6-Dimethyl-5-heptenal [05.074]) Mouse micronucleus 
assay 
NMRI male and female 
mouse bone marrow  
NR 420 - 1540 
mg/kg 
Negative (Wild et al., 
1983) 
Mice received a single dose. Dose levels were 
not justified. The validity of this study cannot 
be evaluated. 
Basc test D. melanogaster NR 25 mM Negative (Wild et al., 
1983) 
Only one dose is mentioned. The validity of 
this study is unclear. 
(Geranyl acetate [09.011]) Mouse micronucleus 
assay 
B6C3F1 mouse bone 
marrow cells 
i.p. 450 - 1800 
mg/kg 
bw/day 
Negative (Shelby et al., 
1993) 
Selection of maximum dose was justified. The 
study is considered valid. 
Unscheduled DNA 
synthesis 
F344 male rats 
hepatocytes 
Oral 
gava
ge 
NR Negative (Mirsalis et al., 
1983) 
Only an abstract is available. The validity of 
this study cannot be evaluated. 
NR = Not Reported.  
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 ABBREVIATIONS 
ADH  Alcohol dehydrogenase 
ADI  Acceptable Daily Intake 
ALDH  Aldehyde dehydrogenase 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoA  Co-enzyme A 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFSA  The European Food Safety Authority 
EH  Epoxide hydrolase 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GSH  Glutathione 
GST  Glutathione S-transferase 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADH  Nicotinamide Adenine Dinucleotide, reduced form  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
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NTP  National Toxicology Program 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
 
